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Abstract 
Rheumatoid arthritis (RA) is an autoimmune inflammatory disease leading to destruction of joint tissue. 
Malfunction of regulatory T cells (Treg) has been implicated in a number of diseases including RA, and several 
studies indicate an increased presence of Tregs in synovial fluid (SF) from RA patients. The marker best defining 
Treg cells is FoxP3, and two low molecular splice forms, FoxP3∆2 and FoxP3∆2∆7, have been identified lacking 
exons 2 and 7. FoxP3 is an intracellular transcription factor involved in the development and function of Tregs. The 
mechanism of function and the importance of the splice forms are not fully understood. 
 The major objective of this PhD project was to examine the expression of Treg relevant molecules CD4, 
CD25, CTLA-4 and the different splice forms of FoxP3 in both peripheral blood (PB) and SF CD4+ T cells from 
RA patients compared to PB CD4+ T cells from healthy controls (HC), and to study the effect of anti-TNF drugs 
on the expression of the splice forms in PB CD4+ T cells. A quantitative real-time PCR method was develop d to 
measure the amount CD4, CD25, and CLTA-4, as well as full length and low molecular splice forms of FoxP3 
mRNA.   
 In a study including 50 RA patients and 10 HC an increase in expression of FoxP3fl and CD25 mRNA was 
observed in RA when compared to HC, but no corresponding increase in CTLA-4. FoxP3∆2 was slightly increased 
in patients compared to HC, and was more abundant th  FoxP3fl in almost all our patients and in every HC. 
However, the increase of FoxP3∆2 was less pronounced than that of FoxP3fl, indicating that FoxP3fl is more 
relevant in relation to the immunopathogenesis of RA. FoxP3∆2∆7 was barely detectable in patient samples and 
not at all in HC. These data suggested an increase in Treg cells with a compromised expression of CTLA-4 in RA 
patients. Since CTLA-4 is thought to be important for contact-dependent suppression by naturally occurring Tregs 
(nTreg), we propose that the nTregs are unable to suppress the ongoing inflammation due to CTLA-4 defici ncy. 
However, based on our data we cannot exclude the possibility of an increase in Treg cells induced in the periphery 
(iTreg) rather than dysfunctional nTregs. 
 In a second study involving paired samples of PB and SF from 17 RA patients we observed a large increase 
of 21-fold in expression of FoxP3fl in SF and a 6-fold increase in PB compared to HC. When comparing the SF to 
the paired PB sample from the same individual, the diff rence in expression between PB and SF appeared to be 
ranked according to sub-diagnosis: RApos < RAneg < PsA, reflecting a high expression in both PB and SF from 
RApos patients. This observation was interpreted as a reflection of an involvement of blood as part of he systemic 
nature of this disease and supports previous reports of an accumulation of Tregs in inflamed joints of RA patients. 
Notably, the FoxP3fl expression in SF CD4+ T cells was highly increased in all patient groups indicating that it is a 
common feature of arthritis and not linked to the aetiology of the arthritis in question. Additionally, a gene 
expression analysis using DNA Microarray was performed on six paired samples (12 arrays) of PB and SF CD4+ T 
cells form three RAneg and three PsA patients. The array data indicated that the increase in expression of FoxP3 
and CD25 mRNA was not due to the presence of activated T cells. 
 In a third study 45 RA patients were followed during 12 weeks of anti-TNF treatment, and the data suggest 
that the TNF decoy receptor Etanercept and the antibody based therapies Adalimumab and Infliximab differ in their 
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effect on FoxP3 expression in responsive patients. Only the decoy receptor Etanercept had an influence o  the 
expression of Treg-relevant markers and reduced the expression of FoxP3fl and CD25 in the responders, though no 
normalization was achieved. This may indicate a reduction in the number of Treg cells. As Etanercept binds both 
TNF-α and Lymphotoxin (LT-α) while the antibodies only target TNF-α, one can speculate that LT-α regulates 
FoxP3 expression in a subset of RA patients. Further it may be speculated that individual patients may experience 
different treatment effect depending on whether the TNF receptor ligand is mainly of monocyte/macrophage origin 
(TNF-α) or T cell origin (LT-α), perhaps adding to the disease heterogeneity. Overall, however, the present 
findings support the view that anti-TNF treatment is mainly symptomatic and not a cure for RA.  
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Dansk resumé 
Leddegigt (reumatoid artritis, RA) er en autoimmun inflammatorisk sygdom, der fører til ødelæggelse af vævet i 
leddene. Funktionssvigt af regulatoriske T celler (Tregs) har været impliceret i en række sygdomme, herunder RA, 
og flere undersøgelser tyder på en øget tilstedeværelse af Tregs i synovialvæsken (SF) fra RA patienter. D n 
markør, der bedst definerer Treg celler, er FoxP3. FoxP3 er en intracellulær transkriptionsfaktor involveret i 
udviklingen og funktionen af Tregs, og to lavmolekylære splejsningsformer der mangler exon 2 og 7, FoxP3∆2 og 
FoxP3∆2∆7, er blevet identificeret. Funktionsmekanismen og vigtigheden af spliceformerne er ikke klarlagt. 
 Formålet med dette PhD projekt var at undersøge ekspr ssionen af de Treg relevante markører CD4, CD25 
og CLTA-4 samt de forskellige FoxP3 splejseformer i CD4+ T celler fra både blod og SF fra RA patienter og 
sammenligne disse med CD4+ T celler fra blod fra raske kontrolpersoner (HC). Yderligere var det formålet at 
undersøge effekten af anti-TNF gigtmedicin på ekspre sionen af FoxP3 splejseformer i CD4+ T celler fra blod fra 
RA patienter i behandling. En kvantitativ real-time PCR metode blev udviklet for at måle mængden af CD4, CD25 
og CTLA-4 samt fuldlængde (FoxP3fl) og de lavmolekyære splejseformer af FoxP3 mRNA. 
 I et studie med 50 RA patienter og 10 HC blev der observeret en stigning i ekspressionen af FoxP3fl og 
CD25 mRNA i CD4+ T celler fra blod fra patienterne i forhold til de raske kontroller, men vi så ingen tilsvarende 
forøgelse af CTLA-4 mRNA hos patienterne. FoxP3∆2 mRNA var lidt øget hos patienter, sammenlignet med HC, 
og var til stede i større mængder end FoxP3fl hos de fleste af patienterne og i alle HC. Men stigningen i FoxP3∆2 
var mindre udtalt end FoxP3fl, hvilket indikerer, at fuldlængde FoxP3 er mere relevant i forhold til patogenesen af 
RA. FoxP3∆2∆7 kunne knapt detekteres i patientprøverne, og slet ikk  hos HC. Disse data tyder på en stigning i 
antal Treg celler med en kompromitteret ekspression af CTLA-4 hos RA patienter. Eftersom CTLA-4 menes at 
være vigtig for de naturligt forekommende Tregs (nTreg) cellekontaktafhængige inhibering, foreslås det, at nTregs 
ikke er i stand til at inhibere den igangværende inflammation pga CTLA-4 mangel. Baseret på de foreliggende data 
kan muligheden for tilstedeværelsen af et øget antal Treg celler induceret i periferien (iTreg) snarere nd 
dysfunktionelle nTregs ikke udelukkes.  
 I et andet studie med parrede prøver af blod og SF fra 17 RA patienter blev der observeret en stor stigning i 
ekspressionen af FoxPfl på 21-fold i SF og en 6-dobling i PB i forhold til HC. Når man sammenligner 
ekspressionen i SF med den parrede blodprøve fra samme individ, ser forskellen ud til at være rangordnet efter 
subdiagnose: RApos < RAneg < PsA hvilket afspejler n høj ekspression i både blod og SF hos RApos patienter. 
Denne observation tolkes her som en afspejling af, at den systemiske karakter af denne sygdom også involverer 
blodet, og den støtter tidligere rapporter om en ophobning af Tregs i inflammerede led hos RA patienter. Navnlig 
den voldsomt forøgede ekspression af FoxP3fl i SF CD4+ T celler hos alle patientgrupper antyder, at dette r et 
fælles træk ved RA og ikke er knyttet til ætiologien af den specifikke subdiagnose. Derudover blev en 
genekspressionsanalyse ved brug af DNA Microarray udført på seks parrede prøver (12 arrays) af blod og SF 
CD4+ T celler fra tre RAneg og tre PsA patienter. Fra disse array data kan det konkluderes, at stigninge  i 
ekspression af FoxP3 og CD25 ikke skyldtes tilstedevær lsen af aktiverede T celler.  
 I et tredie studie blev 45 RA patienter fulgt under 12 ugers anti-TNF behandling, og data tyder på, at TNF 
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decoy receptoren Etanercept og de antistofbaserede behandlinger Adalimumab og Infliximab er forskellige i deres 
effekt på FoxP3 ekspressionen i de responderende patienter. Kun decoy receptoren Etanercept påvirkede 
ekspressionen af Treg relevante markører og reducerede ekspressionen af FoxP3fl og CD25 i de responsive 
patienter, selvom ingen normalisering blev opnået. D te indikerer en reduktion i antallet af Treg celler. Eftersom 
Etanercept binder både TNF-α og lymphotoxin-α (LT-α), mens antistofferne kun binder TNF-α, kan man overveje 
om LT-α påvirker FoxP3 ekspressionen i en delmængde af RA patienterne. Yderligere kan man spekulere om 
enkelte patienter kan opleve forskellig virkning af behandlingen, afhængig af om TNF receptor liganden 
hovedsageligt er af monocyt/makrofag oprindelse (TNF-α) eller T celle oprindelse (LT-α). Overordnet set støtter de 
foreliggende resultater det synspunkt, at anti-TNF behandling primært er symptomatisk og ikke en helbredelse for 
RA.
                                                                                                                                              List of abbreviations 
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List of abbreviations 
Anti-CCP  Anti-cyclic citrullinated protein antibodies 
CD   Cluster of differentiation    
CRP   C-reactive protein 
CTLA-4  Cytotoxic T lymphocyte-associated antigen-4 
DAS28  Disease activity score 28 based on CRP (mg/L) 
FoxP3  Forkhead box protein 3 
FoxP3fl  Full length FoxP3 mRNA 
FoxP3∆2  FoxP3 mRNA lacking exon 2 
FoxP3∆2∆7  FoxP3 mRNA lacking exon 2 and 7 
GAPDH  Glyceraldehyde-3-phosphate dehydrogenase 
HC   Healthy controls 
IDO   Indoleamine 2,3-dioxygenase 
IFN-γ   Interferon gamma 
iTreg   Treg induced in the periphery 
LT-α    Lymphotoxin-α 
MNC   Mononuclear cells 
MonoA  Monoarthritis 
mRNA  Messenger RNA 
MTX   Methotrexate 
nTreg   Naturally occurring Treg 
PB   Peripheral blood 
PCR   Polymerase chain reaction 
PsA   Psoriatic arthritis 
QRT-PCR  quantitative real-time RT-PCR 
RA   Rheumatoid arthritis 
RAneg  Seronegative RA 
RApos  Seropositive RA 
SF   Synovial fluid 
TCR   T cell receptor 
Th1   T helper 1 cell 
Th2   T helper 2 cell 
TNF-α  Tumour necrosis factor alpha 
Treg   Regulatory T cell 
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Short Introduction 
Rheumatoid arthritis (RA) is a chronic inflammatory disease with autoimmune manifestations (Aletaha 2010). RA 
is characterised by inflammation in multiple joints leading to destruction of joint tissue and, consequently, serious 
impairment of joint function. The inflammation in the joint capsule of RA patients is often accompanied by an 
increased amount of synovial fluid (SF) enriched with cells (Feldmann 1996). Among these cells are regulatory T 
cells (Tregs) which are engaged in the maintenance of immunological self-tolerance by direct or indirect 
suppression of self-reactive T and B cells (Fontenot 2003; Hori 2003; Shevach 2006; von Boehmer 2005). A 
paradoxical accumulation of Tregs has been reported both in a number of tumours (Yu 2006), and at sites of 
inflammation such as the synovial fluid of RA patien s (Cao 2004; Raghavan 2009), and malfunction of Tregs may 
play a role in the pathogenesis of RA (Cao 2006; Flores-Borja 2008), making Treg cells an interesting opic for 
further research. Are they different in RA? Why do they not suppress the ongoing inflammation? 
 A relatively new and very expensive therapy of RA consists of targeted intervention against processes in the 
immune system, most often by blockade of proinflammatory cytokines, e.g. TNF-α (Doan 2005; Fox 2000). 
Treatment with these drugs is limited to patients who are not responding sufficiently to other treatments. Only 
about two thirds of the patients achieve an acceptable effect of the treatment (Papagoras 2010) and ideally, patients 
should be screened in advance to sort out who will benefit the most from the treatment. The personal, social, and 
economic consequences of RA are enormous (Albers 1999) as the patients live with pain and disabilities affecting 
their quality of life, functional capacity and working ability. Many questions still remain unanswered garding the 
pathogenesis of RA - the origin of the disease and the chain of events leading to the disease - how is joint 
inflammation initiated? Why does it persist and become destructive? Is specific treatment possible? Currently there 
is no cure for RA, and it is therefore important to keep studying the disease mechanism in order to optimise and 
possibly individualize treatment for the patients.  
 
 
…. 
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Aim 
The overall aim of this study was to gather information on the role of key factors in the pathogenesis of RA in order 
to improve the molecular understanding of the disease. 
 
The specific objectives of the present study were: 
• To establish a quantitative real-time RT-PCR method to measure the relative amount of Treg-related mRNA 
including alternative splice forms of FoxP3 as well as CD4, CD25 and CTLA-4 mRNA. 
• To compare the presence of alternative splice forms of FoxP3 mRNA in blood CD4+ T cells from RA patients 
and healthy controls.  
• To investigate the presence of alternative splice forms of FoxP3 mRNA in CD4+ T cells in synovial fluid from 
RA patients and compare the results to paired samples of peripheral blood CD4+ T cells.  
• To clarify the effect of anti-TNF drugs on the expression of the different splice forms of FoxP3 mRNA in RA 
patients.  
• To investigate if the patients who did benefit from the anti-TNF drugs displayed a different expression pattern 
of FoxP3 mRNA splice forms during therapy.  
• To correlate the relative amount of the different splice forms of FoxP3 mRNA to disease activity and clini al 
parameters.  
 
On the hypotheses that: 
i) A difference in the distribution of FoxP3 mRNA isoforms reflects selective recruitment and activation of Tregs. 
ii) The expression profile of FoxP3 mRNA isoforms in peripheral blood Tregs differs in arthritis patien s when 
compared to healthy controls. 
iii) The expression profile of FoxP3 mRNA isoforms in peripheral blood Tregs is normalized after 12 weeks of 
anti-TNF treatment. 
iv) We are able to identify patients who will benefit the most from anti-cytokine drugs based on its effect on the 
expression of FoxP3 mRNA isoforms present in Treg clls in peripheral blood during therapy.  
v) The distribution of FoxP3 mRNA isoforms in synovial fluid of all three types of arthritis is abnormal compared 
to the blood counterpart and specifically to that of peripheral blood of healthy controls. 
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Background 
Rheumatoid arthritis and psoriatic arthritis 
Rheumatoid arthritis (RA) is a chronic disease affecting 0.5-1 % of the adult population – women more frequently 
than men (Aletaha 2010). RA is a systemic autoimmune disease, characterised by inflammation of the synovial 
joints ultimately leading to erosion and destruction of cartilage and bone, causing pain and disability. RA primarily 
affects the joints, but other organs and tissues such as skin, lungs, and the cardiovascular system ar also known to 
be affected. The patients have increased mortality r te from cardiovascular disease, infection, pneumonia, and non-
Hodgkin’s lymphoma (Naz 2007; Sokka 2008).  
 There is no definite diagnostic test for RA, and the diagnosis is based on clinical symptoms, serological 
changes, and imaging. The current study used the 1987 American College of Rheumatology criteria for RA(Arnett 
1988), shown in table 1, which have been criticized for their lack of sensitivity in early disease. A newer set of 
criteria, the 2010 Rheumatoid Arthritis Classificaton Criteria, have in the meantime been introduced (Aletaha 
2010), focusing on diagnosis at earlier stages of disease rather than defining the disease by its late-st ge features 
(Aletaha 2010). In the papers this thesis is based on, the patients all had established diagnoses of ser positive 
(RApos) or seronegative (RAneg) RA based on the 1987 classification criteria and the presence or absence of 
rheumatoid factor, or the differential diagnoses psoriatic arthritis (PsA) or monoarthritis (MonoA). 
 
Table 1. The 1987 American College of Rheumatology revised criteria for the classification of RA. At least four criteria must 
be satisfied for classification as RA. 
Criteria Definition 
Morning stiffness Morning stiffness in and around the joints, lasting at least 1 hour 
Arthritis of > 3 joint areas 
Soft tissue swelling or fluid in at least 3 of 14 possible areas:  
right or left PIP, MCP, wrist, elbow, knee, ankle, and MTP joints 
Arthritis of hand joints Swelling of the wrist, MCP, or PIP joint 
Symmetric arthritis 
Simultaneous involvement of the same joint areas on both sides of the body 
(bilateral involvement of PIPs, MCPs, or MTPs is acceptable without absolute 
symmetry) 
Rheumatoid nodules Subcutaneous nodules present 
Rheumatoid factor (RF) 
Abnormal concentration of RF as detected by a method at produce positive 
results in < 5% of healthy controls 
Radiographic changes 
Erosions or unequivocal bony decalcification localised to the joints of the hand 
and wrist 
PIP: proximal interphalangeal; MCP: metacarpophalange l; MTP: metatarsophalangeal 
 
 RA is a heterogeneous disease which may be divided into two major subgroups based on the presence or 
absence of autoantibodies such as rheumatoid factor (RF) and anti-cyclic citrullinated protein antibodies (anti-CCP) 
(Nishimura 2007; Quinn 2005). Seronegative RA (RAneg) is characterised by less systemic manifestations, a d a 
better prognosis than seropositive RA (RApos) (da Mota 2009). Anti-CCP are more specific than RF for 
diagnosing rheumatoid arthritis and may better predict erosive disease (Nishimura 2007; Quinn 2005). In this 
thesis, however, RApos refers to the presence of RF only and not anti-CCP. The correlation between the 
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concentrations of the two autoantibodies can be seen in figure 1.  
It is obvious by the distribution, that the two tests correlate, however, due to defined reference ranges, some tests 
are positive in one while negative in the other. Of the 42 patients (those included in paper I and III), represented in 
figure 1, only five were anti-CCP positive and RF negative.  
 
Figure 1. The correlation between RF and anti-CCP. Data from 
42 patients (from paper I and III), where actual numbers were 
available around the time of sample collection, are shown. The 
lines differentiate between positive and negative samples at 17 
kiU/L for RF and 5 kU/L for anti-CCP, respectively. 
 
 
 
 
 
 
 
 Psoriatic arthritis (PsA) (Veale 1994) is another joint disease that resembles RAneg regarding the abs nce of 
RF and anti-CCP. Where RA can affect other organs and tissues such as skin, lungs, and the cardiovascular system, 
psoriasis primarily affects the skin, but gives rise to joint disease, PsA, in up to 30% of the patients. On average 
PsA appears about 10 years after the first signs of p riasis. The classification criteria for PsA are: clinical evidence 
of joint inflammation involving at least one joint for more than 3 months; the presence of at least one psoriatic skin 
lesion and/or dystrophy defined as > 20 nail pits and/or onycholysis; seronegative for RF. If the patient is 
seropositive, he or she is considered to have RA with psoriasis (Veale 1994). However, despite these diff rences all 
three types of arthritis present themselves with similar inflammatory reactions in the joints and may be difficult to 
distinguish clinically from each other (Quinn 2005). PsA patients are given a similar treatment to RA patients with 
anti-TNF drugs. 
 The aetiology of RA is unknown and there are indications of both genetic and environmental factors of 
importance for the development of RA. The main genetic risk factor for RA is “the shared epitope” of the human 
MHC class II, HLA-DR (Gregersen 1987), but since women are affected three times as often as men, estrog ns 
may also be associated with increased risk of RA. The genetic association with HLA-DR suggests a classic l 
immunological mechanism involving CD4+ T cells at some stage in the pathogenesis of RA. The environment 
plays a role, and the main environmental risk factor for RA is smoking (Costenbader 2006; Padyukov 2004), but 
also infectious agents may be a factor (Kobayashi 2008). Certainly, the low concordance rate of 15% betwe n 
identical twins (Silman 1993) suggest that environme tal factors are the major determinants for the onset of 
disease. On the other hand, the concordance rate of 4% in dizygotic twins (Silman 1993) shows that genetic factors 
do contribute.  
 In figure 2 a schematic picture of a healthy and a inflamed joint is presented. In a healthy joint the amount 
of SF is usually very small and contains few cells, if any, while the RA joint often contains increased volume of SF 
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enriched with cells, predominantly neutrophils and granulocytes, but also CD4+ T cells, B cells, macrophages and 
synoviocytes (Feldmann 1996).  
Figure 2. A schematic picture of a 
healthy and an inflamed joint. 
 
 
 
 
 
 
 
 
 
Synovial fluid is routinely aspirated guided by ultrasound at the Parker Institute (Bliddal 2000; Qvistgaard 2001; 
Terslev 2003). There is an increase in cellularity of the synovial membrane, where the thickness is increased from 
1-2 cells to 6-8 cells comprised mostly of activated macrophages with an underlying layer of fibroblast- ike 
synoviocytes. This expansion of synovial membrane forms a structure called pannus that penetrates the cartilage 
and invades the subchondral bone, causing the subseq ent erosion of these tissues (Feldmann 1996). This process 
occurs under the influence of a large number of cytokines. The micro-environment in the inflamed synovium of RA 
patients has been compared to that of tumours with regards to cytokine and chemokine profiles, and to 
neoangiogenesis in the formation of pannus tissue (R dolph 2005). In PsA there is an increased vascularity of the 
skin, and angiogenesis is a prominent event. T lymphocytes are the most common inflammatory cells in the skin 
and joints of PsA.  
 Tumour necrosis factor (TNF) has proven to be a key player in the autoimmune reaction. It is considere  to 
be of major importance in arthritis and is a theraputic target (Doan 2005; Feldmann 1996; Fox 2000; Rubbert-
Roth 2009). The TNF family of cytokines include TNF-α and lymphotoxin-α (LT-α) both binding and signalling 
through the same receptors TNFR1 and TNFR2. TNF-α is a pleiotropic cytokine with multiple actions, and in 
arthritis TNF-α induces e.g. the production of other pro-inflammatory cytokines such as IL-1 and IL-6 and 
chemokines. It also induces the expression of matrix metalloproteinases and prostaglandin E2 by synoviocytes and 
activates osteoclasts, resulting in destruction of cartilage and bone resorption (Brennan 2008; Fox 2000). 
Furthermore, TNF-α activates the T cells, enhancing T cell infiltration, and augments angiogenesis and the 
proliferation of keratinocytes in psoriatic plaques (Veale 2005). The receptors TNFR1 and TNFR2 occur in various 
combinations in different tissues, and the binding of TNF-α to cell surface TNFR1 can also initiate signalling 
pathways that lead to apoptosis or NF-κB activation (Tracey 2008). The importance of TNF-α is highlighted by the 
success of anti-TNF drugs (Taylor 2009). The relative roles of TNF-α and LT-α are not completely elucidated. 
 The first approved biologic agents for the treatment of RA were inhibitors of TNF-α, and the first three 
drugs available of this kind were Enbrel/Etanercept, Remicade/Infliximab and Humira/Adalimumab. The RA
Healthy joint Rheumatoid joint
Capsule
Synovial membrane
Inflamed thickened 
synovial membrane
Cartilage
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patients in paper III were treated with one of these three different anti-TNF drugs. All three drugs bind to TNF-α 
preventing it from activating TNF-α receptors: Remicade/Infliximab is a mouse-human chimeric antibody, and 
Humira/Adalimumab is a chimeric antibody resembling I fliximab, but it contains only human components (Taylor 
2009). Enbrel/Etanercept is a TNF receptor 2-IgG fusion protein, a decoy receptor for both TNF-α and LT-α, and 
contains only human components. Cytokines other than TNF-α have been introduced as therapeutic targets: 
Anakinra is a recombinant form of a naturally occurring IL-1 receptor antagonist, and Tocilizumab is achimeric 
monoclonal antibody blocking IL-6 mediated signal tr nsduction (Taylor 2009). Also, other types of therapies have 
emerged: Rituximab is a monoclonal antibody directed against CD20+ B cells. It induces transient depletion of 
(auto-) antibody production and co-stimulatory B cells (Papagoras 2010). Abatacept is a CTLA-4-IgG fusion 
protein and functions as a selective inhibitor of T-cell co-stimulation by blocking the interaction betw en CD28 and 
the antigen presenting cell (Papagoras 2010).  
 
The Immune System and RA - a brief and selective introduction 
The immune system consists of a myriad of different cell populations and soluble factors, each participating in 
maintaining an effective immune response to infectious agents. It is a common belief that dys-regulated T cells are 
involved in RA based on the well-known HLA association. Additionally, non-cellular agents such as 
autoantibodies, complement factors, and lectins are also involved in the pathogenesis of RA (Okroj 2007). 
Furthermore, microRNAs have recently been implicated in autoimmunity and diseases such as RA (Furer 2010; 
Tili 2008). MicroRNAs are small RNA molecules that regulate gene expression by binding to target mRNAs and 
prevent translation of the protein product by mechanisms involving antisense microRNA-mRNA interaction a d 
subsequent cleavage of the RNAs (Furer 2010; Tili 2008). 
 T cells comprise subsets of lymphocytes developed in the thymus, where the T cell receptor repertoire is 
formed by positive and negative clonal selection. The  cell receptor of the CD4+ T cells reacts to peptid  
fragments presented by MHC class II on the surface of an antigen presenting cell. The CD4+ T cell population may 
be further subdivided into T helper 1 (Th1) and T helper 2 (Th2) cells with somewhat different biological activities: 
The Th1 cells activate macrophages, produce a number of pro-inflammatory cytokines, and stimulate B cells to 
produce antibodies mainly IgG and IgA; while Th2 cells produce anti-inflammatory cytokines and stimulate B cells 
to produce antibodies, especially switching to IgE (Murphy 2008). RA has traditionally been viewed as a Th1-
driven disease with a relative predominance of the T 1 cytokine IFN-γ over IL-4, although neither Th1 nor Th2 
cytokines are present in large amounts in SF (Raza 2005). Th17 cells are a new subset of CD4+ T helper cells that 
have been implicated in immune-mediated tissue injury s ch as in the synovium in RA (Steinman 2007). The
CD4+ Th17 cells stimulate chondrocytes and osteoclasts, nd activates fibroblasts to secrete chemokines (Lubberts 
2004; Lundy 2007).  
 In order to avoid autoimmune reactions the immune system must be able to eliminate or inactivate auto-
reactive cells. Central T cell tolerance is established when T cells specific for self antigens are eliminated in the 
thymus. Occasionally self-reactive T cells may escape deletion in the thymus and enter the periphery. Peripheral T 
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cell tolerance is acquired by mature lymphocytes in the peripheral tissues by cellular inactivation through weak 
signalling without co-stimulus (Murphy 2008). Activated effector T cells specific for self peptide:MHC complexes 
can cause local inflammation by activating macrophages or can damage tissue cells directly. Diseases in which 
these actions of T cells are likely to be important include RA (Cao 2006). A further level of peripheral tolerance is 
obtained through the function of regulatory T cells (see later). 
  
Models for the role of T cells in arthritis 
T cells clearly play a central role in joint inflammation in arthritis, but whether T cells are involved in initiation of 
the disease process, or are secondary to the inflammatory response originating within the joints, is unknown. It is 
also unknown whether the antigen is “an autoantigen (whether specific to the joints or ubiquitous), a highly 
conserved foreign protein cross-reacting with its human homolog, or a neo-antigen expressed as a result of 
posttranslational events” (Fournier 2005). 
 Witebsky’s postulates revisited by Rose in 1993 may be used as the defining criteria for autoimmune 
diseases in human, and they include “direct evidence from transfer of pathogenic antibody or pathogenic T cells; 
indirect evidence based on reproduction of the autoimmune disease in experimental animals; and circumstantial 
evidence from clinical clues” (Rose 1993). For obvius reasons, direct evidence as human-to-human transfe  of 
pathogenic T cells is not possible to come by. Therefore an updated version of the postulates require that “an 
autoimmune reaction is identified in the form of autoantibody or cell-mediated immune reaction; the corresponding 
antigen is known; and an analogous response causes  similar disease in experimental animals” (van Gaalen 2005). 
Several animal models of arthritis, such as collagen-induced arthritis or adjuvant arthritis in rodents, exists and are 
T-cell dependent (Firestein 2003; Fournier 2005). There is general agreement that T cells play a role in arthritis, 
leaving the corresponding antigen to be identified. Several potential candidates have been suggested inclu ing 
collagen type II, proteoglycans, heat shock proteins, a d lately citrullinated proteins (Fournier 2005). 
 van Gaalen proposes a two-step model which emphasizes the involvement of citrullinated proteins and ati-
CCP. The first step involves the presentation of citrullinated proteins to T cells by activated dendritic cells resulting 
in a T cell response. Citrullination is a result of the local inflammatory process and not subjected to regular B-cell 
tolerance development. The T cells stimulate B cells to produce high affinity anti-CCP which then enter the joint 
due to local inflammation or as a result of immune complex-facilitated vascular leakage. The second step involves 
migration of immune cells to the joint during inflammation or after a trauma, citrullination of synovial proteins by 
enzymes activated during cell death, and activation of complement by anti-CCP in complex with citrullinated 
antigens. More immune cells are attracted to the joint, more citrullinated antigens are produced, and  
inflammatory circle contributing to the chronic disease is generated (van Gaalen 2005).  
 Firestein proposes a multi-stage pathogenic model: “a combination of stochastic events (activation of innate 
immunity), pre-determined events (genetic background), and adaptive immune responses directed against 
autologous antigens” (Firestein 2003). The early stage is proposed as activation of innate immunity, and ny 
pathogen that gains entry to the joint could be respon ible in a given individual. Proposed mechanisms are the 
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activation of innate immunity by agonists for toll-like receptors and/or engagement of Fc receptors by 
autoantibodies. Synovial dendritic cells activated by toll-like receptors migrate to the lymph nodes where they 
activate T cells. Adhesion molecules up-regulated on the endothelium allow circulating cells expressing the right 
receptors to accumulate in the inflamed joint. Then, in the appropriate genetic conditions such as the presence of 
the right HLA-DR alleles, there is a loss of tolerance related to the effects of HLA-DR background, or the T-cell 
repertoire might contribute to autoreactivity to newly exposed articular antigens. Direct T cell contact can also 
activate other cells in an antigen-independent manner (Firestein 2002; Firestein 2003).  
 
nTreg and iTreg 
Dysfunctions of Tregs fit the afore mentioned models as they are probably primed in the lymph nodes and l ter 
summoned to the joint by chemokines and adhesion molecules. Tregs are dedicated to the task of specializing in 
suppressing the activation, expansion, and function of other T cells and B cells (Fontenot 2003; Hori 2003; 
Shevach 2006; von Boehmer 2005). Hereditary as well as experimental elimination of Tregs lead to autoimmune 
manifestations (Afzali 2007; Allan 2008; Flores-Borja 2008; Hori 2003; Sakaguchi 2008), and quantitative or 
qualitative abnormalities in Tregs may contribute to inflammation in RA. There are a number of T cell subsets with 
immune modulating function (Cools 2007), however, the focus of the present thesis is the FoxP3 expressing T cell 
subsets, nTregs and iTregs, described below. 
 Current evidence suggests the existence of two subsets of FoxP3 expressing Tregs, the natural (nTreg) and 
the induced (iTreg) Treg cells (Horwitz 2008; Khattar 2009). nTregs develop in the thymus and then migrate to the 
periphery where they comprise 5-10 % of T cells. nTregs are characterised by the expression of cell surface 
markers CD4, CD25high, CD127low, and also CTLA-4 and glucocorticoid-induced tumour necrosis factor 
receptor (GITR). nTregs express FoxP3high, an intracellular transcription factor. The iTregs are generat d in the 
periphery from CD4+CD25- cells after antigen recognitio  and in the right environment rich in TGF-β. iTregs start 
to express some of the same cell markers as nTregs (CD4, CD25low, and FoxP3low) (Horwitz 2008; Khattar 
2009). CTLA-4 is one of the key molecules in Treg clls and is supposed to take part in the development of iTregs 
(Curotto de Lafaille 2009; Horwitz 2008) as well as in the suppressive mechanism of Tregs. Another difference 
between nTregs and iTregs is the differential sensitivity to modulation of the suppressive capacity upon interaction 
with IL-6 (Zheng 2008). 
 Both nTregs and iTregs need triggering of their T cell receptor (TCR) for suppressive function (Cools 2007). 
The TCR specificity of Tregs is currently unknown, but a model has been proposed predicting differences in 
specificity of the TCR between nTregs and iTregs (Fujimoto 2011; Horwitz 2008). As Tregs are CD4+, theantigen 
is expected to be presented by MHC II. It has been speculated that since activated T cells express MHC II, the 
thymus-generated nTregs are selected to recognise self-peptide including TCR fragments on activated T cells. In 
contrast, iTregs are generated from conventional activated T cells, and accordingly their TCR repertoire is expected 
to be directed against foreign antigen fragments pre ented by antigen presenting cells (Vandenbark 2008). 
 Isolation of highly purified Tregs is difficult and time consuming because there is no unique cell surface 
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marker, and because Tregs share phenotypic similarities with activated T cells (Aerts 2008; Bour-Jordan 2009; 
Milpied 2009). FoxP3 is the marker best correlated to Treg cells (Hori 2003; Khattri 2003; Ramsdell 2003), but it is 
a transcription factor located in the nucleus and it is therefore difficult to determine with flow cytometry. The 
staining of FoxP3+ cells can be highly variable anddepends on the choice of antibody/buffer pair and the setting of 
the FoxP3 gate (Law 2009). Additionally, the estimaon of FoxP3+ cells in flow cytometry and western blot has 
been further complicated by cross-reactivity with until now unidentified proteins of a FoxP3 antibody commonly 
used in flow cytometry (Woetmann, personal communication).  
 
The mechanism of action 
The mechanism of action is thought to be different for he two subsets – the nTregs suppress primarily via a cell 
contact-dependent mechanism, while the iTregs suppress through a cell contact-independent mechanism using
cytokines such as IL-10 and TGF-β (Ramsdell 2003; Tang 2004). It is likely, that there is more than one 
mechanism by which Treg cells exert suppression, and that they do so in a context-dependent manner depending on 
several factors, for example the target cell, the local cytokine milieu, and the activation status of the antigen 
presenting cells.  
 One possible mechanism for cell contact-dependent suppression through CTLA-4 is the aggregation of Tregs 
on dendritic cells resulting in down-modulation of the CD80 and CD86 molecules on the dendritic cells, as 
described in mice (Oderup 2006; Onishi 2008). CD80 and CD86 provide a co-stimulatory signal through CD28 
which is necessary for T cell activation and survival. Down-modulation of this signal would result in suppression 
of T cell activity. CTLA-4 and CD28 are similar molecules, and both bind to CD80 and CD86 but with opposite 
effect, the former inhibitory and the latter stimulatory (Magistrelli 1999). Another suppressive mechanism 
involving CTLA-4 is the induction of indoleamine 2,3-dioxygenase (IDO) in dendritic cells through the int raction 
between CTLA-4 and CD80/CD86. IDO is an enzyme involved in tryptophan catabolism in dendritic cells, and 
cells expressing IDO can suppress T cell responses through deprivation of the essential amino acid tryptophan and 
promote tolerance (Mellor 2004). A different proposed mechanism of immune suppression is the inactivation nd 
conversion of extracellular ATP to AMP by the cell surface associated ectonucleotidase CD39, present on FoxP3+ 
Treg cells (Borsellino 2007). Extracellular ATP is released by damaged cells and functions as an activator of pro-
inflammatory responses, and as a chemo-attractant for lymphocytes (Bours 2006). An additional suppressive 
mechanism involving cAMP is the formation of GAP junctions between Tregs and effector T cells allowing cAMP 
to diffuse from inside the Treg cell to inside the effector T cell (Bopp 2007) resulting in the inhibit on of T-cell 
activation. Yet another proposed mechanism is the consumption by Treg cells of survival and growth promoting 
cytokines, such as IL-2, resulting in induction of apoptosis in effector T cells (Pandiyan 2007; Scheffold 2007). 
Tregs express high levels of the IL-2 receptor, CD25, but do not produce IL-2 themselves. This mechanism of 
action may be lost when large amount of cytokines ar  available, such as in the arthritic joint. 
 Another example of the importance of cytokines is the balance between the anti-inflammatory Treg cells and 
the pro-inflammatory Th17 cells. The cytokine TGF-β is required for both Treg and Th17 differentiation, as it 
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induces the expression of the transcription factors F xP3 and RORγt required for differentiation of the Treg and 
Th17 cell lineages, respectively. FoxP3 can inhibit RORγt transcriptional activation resulting in Treg 
differentiation and not Th17, but in the presence of IL-6 the effect is abrogated leading to Th17 differentiation and 
not Tregs (Ivanov 2006; Zhou 2008). Th17 cells are also involved in activation of osteoclasts, causing bone 
resorption (Steinman 2007), and the role of IL-17, produced by Th17 cells, includes promotion of neutrophil 
accumulation and release of pro-inflammatory cytokines by a wide range of cell types (Brennan 2007; Xu 2010). 
 Also TNF-α is important in RA and has been shown to inhibit the suppressive function of Treg cells 
(Valencia 2006). Treg cells express TNFR2, and signalling through this receptor resulted in reduced FoxP3 
expression and decrease in suppressive function. Supposedly anti-TNF treatment restored their suppressiv  
function (Valencia 2006).  
 
FoxP3 
The marker best correlated to Tregs is the transcription factor FoxP3, which controls the expression of a number of 
key genes in the Treg cell itself and is required for the development of suppressive function of Treg c lls (Hori 
2003; Khattri 2003; Ramsdell 2003). However, there are reports that FoxP3 is transiently expressed in human 
activated non-regulatory T cells, although in significantly lower levels than those in suppressive nTregs (Allan 
2007; Wang 2007). Supposedly, this transient expression of FoxP3 is a consequence of CD4+ T cell activtion and 
the activated cells do not convert to Tregs (Allan 2007). 
Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7Exon 1 Exon 8 Exon 9 Exon 10 Exon 11Full length FoxP3
FoxP3 ∆2∆7
Exon 3 Exon 4 Exon 5 Exon 6 Exon 7Exon 1 Exon 8 Exon 9 Exon 10 Exon 11FoxP3 ∆2
Exon 3 Exon 4 Exon 5 Exon 6Exon 1 Exon 8 Exon 9 Exon 10 Exon 11
FoxP3              
Repressor Region Zink Finger     Leucine Zipper Forkhead Domain
 
Figure 3. Schematic structure of the coding exons of human FoxP3 mRNA and the splice forms, and the predicted sructural 
and functional domains. Modified from paper I (Ryder 2010). 
 
Patients with genetic deficiencies in FoxP3 develop severe abnormalities in immune homeostasis, the IPEX 
syndrome (Immunodysregulation, Polyendocrinopathy, Enteropathy, X-linked), causing e.g. excessive cytokine 
production, and chronic inflammation leading to death (van der Vliet 2007).  
 The FoxP3 gene consists of 12 exons, but the first exon in the 5’ end is not translated and therefore dubbed 
exon -1. There is consensus that FoxP3fl comprise of exon 1-11. Two low molecular splice forms of FoxP3 have 
been found, FoxP3∆2 and FoxP3∆2∆7. As can be seen in figure 3, they both lack exon two, and the FoxP3∆2∆7 
isoform also lacks exon seven (Allan 2005; Krejsgaard 2008; Smith 2006). Exon two is a part of the proline-rich 
repressor region at the N-terminal part of the protein, which has been shown to be important for transcriptional 
repression by FoxP3 (Bettelli 2005; Du 2008; Lopes 2006). Exon seven is part of the leucine zipper domain 
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necessary for FoxP3 homodimerization (Lopes 2006). The Forkhead/winged helix domain at the C-terminal of the 
FoxP3 protein mediates its nuclear localisation and ability to bind DNA (Schubert 2001).  
 The full length FoxP3 protein acts as functional repressor of RORα, NFAT, and NF-κB mediated gene 
expression (Bettelli 2005; Du 2008; Krejsgaard 2008). RORα has been implicated in the maintenance of bone 
tissue (Meyer 2000) and as a negative regulator of inflammatory response (Delerive 2001), and NF-κB and NFAT 
are among other things essential for cytokine gene expression and T cell functions (Bettelli 2005). The two 
isoforms differ functionally from FoxPfl, although t e lack of exons two and seven did not prevent FoxP3-
dependent inhibition of T-cell activation (Smith 2006). The FoxP3∆2 splice variant differs functionally from full 
length by not being able to interact with RORα and inhibit RORα-mediated transcriptional activation (Du 2008). 
Both low molecular isoforms of FoxP3 have no inhibitory effect on NF-κB transcriptional activity, while the full 
length version is a strong inhibitor (Bettelli 2005; Krejsgaard 2008). There are, however, conflicting results 
regarding the splice variants as another group showed that all isoforms reduced both NFAT-mediated and NF-κB-
mediated transcription, and that the lack of exon seven did not affect dimerization (Mailer 2009). On the other 
hand, previous reports have identified exon two as a central part of the transcriptional repressor domain in FoxP3 
(Bettelli 2005; Du 2008; Lopes 2006).  
 The focus of this thesis is Tregs isolated from arthritis patients. For logistic reasons (e.g. lack of equipment, 
money, time) I have not performed any flow cytometry o  functional studies of these Tregs. At the time th se data 
were generated, no antibodies able to distinguish between the different isoforms of FoxP3 were available for flow 
cytometry, and it has only recently been possible to buy kits for isolation of a highly purified Treg population. 
Hence, I decided to isolate CD4+ T cells using magnetic beads, and froze the cells for RNA extraction. Functional 
as well as flow cytometry data are most reliable whn performed on freshly isolated cells, and therefore a post-hoc 
analysis was not in question.  
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Methods 
Validation of the QRT-PCR 
The choice of reference gene for QRT-PCR 
In all samples, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and CD4 were used as reference genes. It is 
standard to use housekeeping genes such as GAPDH as an internal reference gene to normalize the PCRs for the 
amount of RNA added to the initial cDNA reactions. A commercially available ready-to-use GAPDH TaqMan 
Assay Reagent was used. As the focus of this work was FoxP3-expressing CD4+ T cells isolated by CD4 positive 
selection, the CD4 gene was used as cell-specific control gene. It was not possible to do an actual control of the 
reference genes, as the material used originated from patients and was not subjected to controlled experimental 
variation. However, Mocellin demonstrated that the gene expression of CD4 by resting T cells did not change 
significantly after stimulation and it is therefore suitable to use as a T cell subset-specific reference gene (Mocellin 
2003). Hence, the cycle threshold (Ct) values were no malized against the corresponding CD4 values. Additionally, 
there was a positive correlation between the Ct values of GAPDH and CD4 in blood CD4+ cells from arthritis 
patients, see figure 4, and the Pearson product moment correlation coefficient (R2) was calculated in Excel to be 
0.953. Because 95.3% of the variance in Ct(CD4) was attributable to the variance in Ct(GAPDH) it was as umed to 
be safe to replace GAPDH with CD4. 
 
Figure 4. The correlation between GAPDH and CD4 Ct 
values. Data from 50 patients included in the study (paper I) is 
shown. The trendline equation was obtained using Microsoft 
Excel. 
 
 
 
 
 
 
 
 
The principle 
The quantitative real-time RT-PCR method theoretically doubles the amount of DNA with every cycle. The 
principle of the QRT-PCR reaction is outlined in figure 5. In short, the Taqman probe consists of a DNA sequence 
modified with a reporter dye in the 5’ end and a quencher in the 3’ end. When the quencher is in close proximity of 
the dye, it quenches the fluorescence signal by the phenomenon of fluorescence resonance energy transfe . During 
the PCR cycle the Taqman probe is cleaved, releasing the reporter dye from the effect of the quencher. The 
instrument quantitatively measures the fluorescence generated after each PCR cycle, and the expression of a gene is 
quantified in terms of cycle threshold (Ct). The Ct is the number of cycles at which the measured fluorescence 
exceeds the determined threshold. Hence, a large Ct for a given target gene translates to a small amount f starting 
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material and vice versa. 
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Figure 5. The principle of the QRT-PCR reaction. Reporter dye: 6-FAM; Quencher: TAMRA 
 
 The big question is how to analyze these RT-PCR data, and there are two methods one can use: the relative 
quantification and the absolute quantification. The absolute quantification method determines the starting copy 
number usually by relating the specific signal to a standard curve. The relative quantification method is used to 
analyze relative changes in gene expression by relating the specific signal in one sample to another, e.g. PB versus 
SF; before and after treatment. I chose relative quantification using the 2 – ∆∆Ct method (Livak 2001), where ∆∆Ct = 
∆Ct(target, patient) – ∆Ct(target, healthy control group). The relative expr ssion was calculated as the amount of 
target normalized to the internal reference CD4, and relative to the healthy controls used in the comparison in paper 
I, II, and III. Additionally, when comparing the individual expression levels in SF relative to the expr ssion in 
paired samples of PB in paper II the expression in SF was calculated relative to the paired PB sample, and  
∆∆Ct = ∆Ct(target, SF) – ∆Ct(target, PB). 
 
Assumptions, dilutions, slopes, and efficiencies 
When applying the 2 – ∆∆Ct method to QRT-PCR data it is assumed that the amplification efficiencies of the target 
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and reference transcripts are approximately equal. The efficiency is derived from the theoretical function for the 
amount of PCR product formed: N = N0 * E
n, where N is the number of amplified copies, N0 is the starting number 
of copies, n is the number of amplification cycles and E is the efficiency (Mygind 2002). The ideal efficiency is 2, 
and theoretically the amount of copies is doubled with every PCR cycle. The efficiency can be calculated from the 
slope of the line in the plot of log cDNA dilution (x-axis) versus Ct (y-axis). The equation below is derived from 
the function above:  
n = - (1/logE)*logN0 + (logN/logE), and the slope equals -(1/logE) (Mygind 2002).  
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Figure 6. 10-fold dilutions series of cDNA using primer sets for A) CD4 and B) FoxP3fl. The slopes were determined from 
the trendline equations. 
 
 
 A ten fold serial dilutions of cDNA were amplified using all primer sets and plotted as described above. In 
figure 6 the plot for CD4 and FoxP3fl dilution series are shown, and the plots for the remaining five systems are 
shown in Appendix D. The slopes were determined from the trendline equations in the Excel plots, and the 
efficiency of each primer pairs were calculated as st ted above and shown in table 2. 
 
Table 2. The slopes and efficiencies of each probe and primer pairs in the QRT-PCR. 
 GAPDH CD4 CD25 CTLA-4 FoxP3fl FoxP3∆2 FoxP3∆2∆7 
Slope -3.33 -3.31 -3.44 -3.31 -3.20 -3.36 -3.57 
Efficiency 2.00 2.01 1.95 2.01 2.05 1.98 1.91 
 
 The ideal efficiency is 2.00 and the corresponding slope is - (1/log2) = 3.32. There are no rules as to how 
similar the efficiencies have to be in order to usethe 2 – ∆∆Ct method. Schmittgen suggests that the efficiency of tw  
genes are similar enough if they are within 10% of each other, that is efficiencies in the range of 1.8 to 2.2 with 
corresponding slopes of -3.92 to -2.92 (Schmittgen 2008). So what is the effect of difference in efficiency between 
target and reference gene? This can best be illustrated by an example. At cycle number 25 with efficien s of 1.8 
and 2.0, and using the equation above, there is difference in Ct of 3.7 corresponding to a 13-fold difference:  
N = N0*E
n = N0*1.8
25 = N0*2.41*10
6 and N = N0*E
n = N0*2.0
25 = N0*3.36*10
7  
 During the experimental work it was discovered that e primer pair amplifying FoxP3fl were suboptimal. A 
new pair was designed and tested using the existing taqman probe, see figure 6 above. Data using both the new and 
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old primer pairs were compared, showing differing results only if the Ct values obtained using the old pair were 
higher than 32. As a consequence all samples with a Ct v lue higher than 32 in that particular system were 
reanalyzed with the new set.  
 
TRIzol versus KingFisher 
For practical reasons I used two different RNA isolati n methods, the automatic KingFisher technology using 
magnetic rods and magnetic beads with oligo-dT probes catching mRNA, and the TRIzol reagent method isolating 
total RNA. In order to certify that the two methods of RNA isolation were comparable I performed two separate 
RNA extractions on the same samples using both methods followed by cDNA synthesis and QRT-PCR. The 
samples used were CD4+ T cells from PB and SF from an RA patient. Sample preparation and total RNA isolation 
using TRIzol Reagent were described in paper II, while real-time quantitative RT-PCR and mRNA isolation using 
the KingFisher technology were described in detail in paper I.  
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Figure 7. The numerical difference in ∆∆Ct for the two RNA isolation techniques used when A) GAPDH and B) CD4 was 
used as reference gene. |∆∆Ct(GAPDH)| = |∆CtTRIzol(target gene) – ∆CtKingFisher(target gene)| where ∆Ct(target gene) = 
Ct(target gene) – Ct(GAPDH). For the calculation of |∆∆Ct(CD4)| the Ct(GAPDH) values were substituted with the Ct(CD4) 
values. 
 
To ensure comparability and to correct the results for differing amounts of RNA I used GAPDH as referenc  and 
calculated the ∆Ct value for CD4, CD25, CTLA-4, and the three FoxP3 splice forms as ∆Ct(target gene) = 
Ct(target gene) – Ct(GAPDH). The differences in ∆Ct values between the two methods were less than one for all 
target genes (figure 7), and I therefore assume the two methods are comparable. I repeated the calculation for each 
target gene replacing the Ct values for GAPDH with CD4, and obtained similar results with differences in ∆Ct 
values of less than one (figure 7). 
 
Synovial fluid samples – volumes and cell numbers 
In the paired samples study (paper II) all rheumatic patients with flare in the knee joint from whom a cellular SF 
could be obtained were included. Volumes of SF aspir ted were between 22-285 ml with a median volume of 50 
ml. The number of MNC isolated from each sample varied between 0.08-3.2 x 106 MNC/ml. The percentage 
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represented by MNC was different from patient to patient. Some patients had a large percentage of 
granulocyte/macrophages others a few, based on personal observations of the precipitate after Lymphoprep 
gradient centrifugation. 
 
Clinical parameters 
In paper I and III we tested the correlation between the presence and amount of FoxP3 mRNA and several clinical 
parameters. In this section I would like to describe these parameters with a few more words. 
 
DAS28 score 
The DAS28 score is a validated tool for quantitative assessment of RA (Prevoo 1995; van Gestel 1998; Wells 
2009). It is a combined measure of information on swollen joints, tender joints, the acute phase respon e CRP and 
the patient assessment of general health. DAS28 provides a number on a scale from 0 to 10, indicating the current 
activity of arthritis in the patient. A DAS28 score of above 5.1 translates to a high disease activity whereas a 
DAS28 score below 3.2 indicates low disease activity. DAS28-defined remission is classified as a score lower than 
2.6. Remission is the state of absence of disease activity in patients with a chronic illness, with the possibility of 
return of disease activity. The DAS28 score is used in both patient care and clinical research. The EULAR response 
criteria (Aletaha 2010) includes changes in disease activity, as well as current disease activity, andstates that good 
responders are patients with an improvement of > 1.2 and a present score of ≤ 3.2. DAS28 scores are calculated as 
follows, where TJC = Tender joint count; SJC = Swollen joint count; GH = general health using the 100 mm visual 
analogue scale (VAS); and CRP mg/L.  
DAS28 = 0.56*√(TJC28) + 0.28*√(SJC28) + 0.014*GH + 0.36*ln(CRP+1) + 0.96 
 
CRP 
C-reactive protein is one of the plasma proteins known as acute-phase proteins. They are proteins which may 
increase or decrease their plasma concentrations by 25% or more during inflammation. Conditions that commonly 
lead to marked changes in CRP include infection, trauma, surgery, burns, advanced cancer, and inflammatory 
conditions such as RA. CRP is produced in the liver (Brahn 1988), and the production is stimulated by the 
cytokines IL-6 and TNF-α. At Frederiksberg Hospital a normal CRP value is defined as <10 mg/L. 
 
VAS 
Self-reported general health assessment using the 100 mm visual analogue scale (VAS) where 0 = best and 100 = 
worst. 
 
HAQ 
The health assessment questionnaire (HAQ) is a questionnaire that evaluates self-perceived physical disability to 
perform different activities of daily living grouped into eight areas: dressing and grooming, rising, eating, walking, 
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hygiene, reaching, gripping, and other activities. The HAQ result in a number between 0-3 where 0 is normal and 3 
is indicating severe physical disability. 
 
ESR 
The erythrocyte sedimentation rate (ESR) measures the ra e at which red blood cells separate from blood serum 
over time, becoming sediment in the bottom of the test ube. The sedimentation rate increases with inflammation 
mainly due to elevated concentrations of fibrinogen (Brahn 1988), and at Frederiksberg Hospital a normal ESR 
value lies within 2-20 arbitrary units. 
 
Anti-CCP 
Some patients develop antibodies against modified (citrullinated) arginine residues (anti-CCP). Citrullination 
results in a small change in molecular mass and the loss of a positive charge in the modified proteins (van Gaalen 
2005). The physiological role of citrullination remains to be elucidated. At Frederiksberg hospital a normal anti-
CCP value is < 5 kU/L.  
 
RF 
Rheumatoid factor (RF) is an autoantibody against the Fc portion of IgG. RF is a combination of autoanibodies 
from the three major classes of immunoglobulins IgM, IgG, and IgA, with the IgM and IgG as the most abundant 
(Mannik 1988). RF forms immune complexes with the IgG and can be used prognostically as it correlates with 
functional and radiographic outcomes in RA. At Frederiksberg hospital a patient is defined positive at a RF 
concentration > 17 kiU/L.
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Results & Discussion 
We established a QRT-PCR method to measure the relative amount of Treg-related mRNAs  
We designed assays for Treg relevant markers CD4, C25 and CTLA-4. We also designed four FoxP3 assays e ch 
amplifying different transcripts (figure 8, paper I+II+III). The assays were designed with primers or probes 
spanning exon-exon junctions to avoid amplification of genomic DNA. Samples were run in duplicates starting 
with the reverse transcription step, and a sample specific control containing mRNA, but without random hexamer, 
RNase inhibitor or reverse transcriptase was included in the QRT-PCR analysis. These samples were negativ  and 
served as a control for the amplification of genomic DNA.  
 
Probe APrimer B
Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7Exon 1 Exon 8 Exon 9 Exon 10 Exon 11Full length FoxP3
Exon 3 Exon 4 Exon 5 Exon 6 Exon 7Exon 1 Exon 8 Exon 9 Exon 10 Exon 11FoxP3 ∆2
FoxP3 ∆2∆7 Exon 3 Exon 4 Exon 5 Exon 6Exon 1 Exon 8 Exon 9 Exon 10 Exon 11
Primer C
Primer C
Probe A
Probe D
 
Figure 8. Schematic structure of the coding exons of human FoxP3 mRNA and the splice forms. From paper I (Ryder 2010). 
 
The efficiencies were determined to be the same for all systems. The largest difference in efficiency was between 
the CD4 and FoxP3∆2∆7 (splice form lacking exon 7) primer pairs with efficiencies of 2.01 and 1.91, respectively. 
At cycle number 25 with these efficiencies and using the equation mentioned before, there is a 1.8 difference in Ct 
values corresponding to a 3.6-fold difference:  
N = N0 * E
n = N0 * 2.01
25 = N0 * 3.80*10
7 and N = N0 * E
n = N0 * 1.91
25 = N0 * 1.06*10
7  
 Unlike the other FoxP3 assays, the one amplifying the splice form lacking exon 7 gave very large Ct values, 
which translates to very small amounts of that particular splice form. We can therefore conclude that e assay 
measuring splice forms lacking exon 2 is mainly measuring FoxP3∆2, and that: 
FoxP3∆2 + FoxP3∆2∆7 ≅ FoxP3∆2.  
It is also worth mentioning that when the concentration of template is close to one molecule pr well, the 
distribution of template molecules per well is expected to follow the Poisson distribution (the Poisson law of small 
numbers). For example, if the concentration is one copy of cDNA per well, you would expect no signal in 37% of 
the wells.  
 
Increased expression of FoxP3 mRNA in blood CD4+ T cells from RA patients compared to HC 
In our studies (paper I+II+III) both full length and the ∆2 splice form of FoxP3 were present in PB cells in patients 
as well as in HC; and the ∆2 splice form was more abundant than the full length version in almost all our patients 
and in every HC. In paper I we found an increased expression of FoxP3fl and CD25 mRNA in the patients 
compared to the healthy control group, but no significant difference in FoxP3∆2 or CTLA-4 mRNA levels between 
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the two groups. In our second study (paper II) our data on PB CD4+ T cells from RA patients differed slightly from 
that of our first study (paper I). In the second study, we found a significant increase in expression of both FoxP3fl 
and ∆2 in RA patients compared to HC, and a non-significant increase in CD25 mRNA, while the CTLA-4 mRNA 
levels were significantly lower. However, the overall tendencies in both studies were the same: increased mRNA 
levels of CD25 and both full length and ∆2 splice forms and decreased levels of CTLA-4 mRNA (figure 9). 
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Figure 9. Comparison of the individual expression levels (mRNA) in peripheral blood CD4+ T cells of A) FoxP3fl, B) 
FoxP3∆2, C) CD25, and D) CTLA-4 in the RA patients in paper I + II and 10 healthy controls relative to the av rage 
expression of the healthy controls. A fold change above 1 represents an increase, and a fold change below 1 represents a 
decrease. The mean value is shown with a bar. *p<0.05, ** p<0.01, ns: not significant. 
 
 We interpreted these data in support of the hypothesis that Tregs are increased in RA patients, but suggested, 
however, that these Tregs had a compromised expression of CTLA-4. CTLA-4 is thought to play an important part 
in the suppressive function of nTregs (Flores-Borja 2008; Tang 2004), and the relative deficiency of CTLA-4 
expression could also indicate the presence of iTregs ather than nTregs. These findings were in accordance with 
previously published data suggesting increased numbers of Tregs in RA patients (Cao 2004; Mottonen 2005; 
Raghavan 2009), as well as non-functional Tregs prior to anti-TNF treatment (Ehrenstein 2004; Flores-Borja 2008; 
Nadkarni 2007). An alternative interpretation could be an increased expression of FoxP3 and CD25 in single cells 
and not an increase in numbers, but it is more likely a combination of the two. We are looking at the av rage CD4+ 
cell, and cannot distinguish between a few cells expr ssing large amounts or many cells expressing small a ounts. 
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Also, it is important to remember that the amount of mRNA is not directly proportional to the amount of protein 
produced. A large increase in expression of FoxP3fl mRNA does not necessarily correspond to a large incr ase in 
FoxP3fl at the protein level. 
 Recently, a novel splice variant of FoxP3 lacking o ly exon 7 was identified in ex vivo stimulated 
CD4+CD25+ T cells and CD8+ T cells (Kaur 2010). Kaur reported an increase in expression of FoxP3∆7 by up to 
136-fold in ex vivo stimulated CD4+CD25+ T cells. They also detected the FoxP3∆7 splice form in freshly isolated 
CD4+CD25+ T cells comprising <1% of total FoxP3 (Kaur 2010). The FoxP3∆2∆7 isoform has been found to be 
over-expressed in Sézary Syndrome, an aggressive variant of cutaneous T cell lymphoma (Krejsgaard 2008). A 
disadvantage of the QRT-PCR technique is that it is not possible to quantify the double deletion splice form such as 
FoxP3∆2∆7 directly. In our dataset the splice form lacking exon seven, with or without exon two, was not 
measurable in the ten healthy controls and only expressed in small amounts in the RA patients, suggesting that 
CD4+ T cells from arthritis patients predominantly express FoxP3fl and FoxP3∆2. Also, sequencing of FoxP3 from 
23 cloned bacterial colonies (paper I) revealed that none of them was missing exon seven. In our dataset he ∆7 
isoform, with or without exon two, was not very common. 
 A physiological role of these different splice forms has yet to be found. Alternative splicing allows a gene to 
produce more than one isoform of mRNA, often resulting in functionally distinct proteins. It is a well-known, albeit 
not well-characterised, phenomenon in the immune system and in activated T cells (Grigoryev 2009; Ip 2007; 
Lynch 2004). One known example of alternative splicing in T cells are the markers CD45RA and CD45RO, used 
to distinguish between memory CD45RO T cells and virgin CD45RA T cells, where the CD45RO splice form is 
lacking three exons (Hermiston 2003; Holmes 2008; Oberdoerffer 2008). Another example is the alternative splice 
form of the cytokine IL-7 lacking exon 5 (Vudattu 2009). The FoxP3 splice forms are functionally distinct, and 
especially exon two has been identified as a central part of the transcriptional repressor domain able to interact with 
RORα (Du 2008). A change in the balance between the diff rent isoforms within the Treg cell might affect the 
ability of FoxP3 to interact with different transcription factors and molecules and mediate a change in ne 
expression and cell function. Thus it may be hypothesised that the Tregs found in RA represent a stage of frustrated 
Tregs incapable of suppressing the inflammatory process. Alternative splice forms in general might represent 
therapeutic targets and/or candidates for diagnostic u e. 
 
What is the difference between the PB CD4+ T cells presented in paper I and II? 
In the paired samples study (paper II), irrespectiv of sub-diagnosis and treatment, all rheumatic patients with flare 
in the knee joint from whom a cellular SF could be o tained, were included. These patients were included on short 
notice on the day the knee was aspirated, contrasting the patients in the first study (paper I) who participated in a 
planned and scheduled course of treatment. The data on the patients in the first study (paper I) were baseline data 
prior to treatment with anti-TNF drugs, which are used for treatment based on a most often wide spread disease 
activity. In contrast, the patients in the paired samples study (paper II) were included based on a flare in a single 
joint, i.e. a more local phenomenon. 
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An overall increase in expression of FoxP3 in CD4+ T cells in SF compared to PB in RA patients 
Analysis of the expression of FoxP3 mRNA in paired samples of CD4+ T cells from PB and SF (paper II) 
confirmed the overall increase in expression of FoxP3 splice forms in arthritis patients compared to healthy PB 
CD4+ T cells. Especially, FoxP3fl was noticeably increased with a fold change of 21.3 in SF and 6.7 in PB CD4+ 
T cells from arthritis patients when compared to HC. Also the ∆2 splice form was increased in the patients 
compared to HC although not as dramatically with a fold change of 6.0 in SF and 2.1 in PB CD4+ T cells. 
Furthermore CD25 was increased with a fold change of 2.8 in SF and 1.6 in PB (not significant) compared to HC, 
while the expression of CTLA-4 was decreased in PB from RA patients with a fold change of 0.4 (corresponding to 
-2.5) compared to HC. The expression of CTLA-4 in SF was equal to that in PB from HC.  
 The full length version of FoxP3 is a well-characterised marker of Treg cells and plays an important role in 
the induction of fully functional Treg cells (Hori 2003; Yagi 2004), while the importance and function of the two 
low molecular splice forms are not fully elucidated. Thus, our data on the selective increase in expression of 
FoxP3fl in SF support previous reports of an accumulation of Tregs in inflamed joints of arthritis patients (Cao 
2006; Jiao 2007; Mottonen 2005; Van Amelsfort 2004). Additionally, the high increase in FoxP3 expression 
without a concomitant increase in CTLA-4 expression in blood and SF support the hypothesis of abnormal Tregs 
with a compromised function in RA (Flores-Borja 2008), both in the inflamed joint but also systemically. It could 
be explained as an increase in iTreg cells, as this cell population uses a contact-independent mechanism of 
suppression which does not involve CTLA-4. 
 When comparing the individual expression levels of the different splice forms of FoxP3 in samples of SF 
CD4+ T cells relative to the expression in paired samples of PB CD4+ T cells (paper II), the patients displayed a 
differentiated expression pattern based on the arthritis sub-type. The three splice forms were increased in SF 
compared to PB in RAneg and PsA, but not in RApos. The RApos patients had a high FoxP3 expression in both PB 
and SF CD4+ T cells. The PB-SF ratio of FoxP3 mRNA splice forms appeared to be ranked according to diagnosis: 
RApos < RAneg ≤ PsA. Although the ranking was not as clear for the expression of the low molecular splice forms 
as it was for FoxP3fl, a definite trend was observed. The marked increase in FoxP3fl expression in SF CD4+ T 
cells in all patients irrespective of specific sub-diagnosis compared to HC indicated that it is a comm n feature of 
arthritis and not linked to the pathology of the arthritis in question. The observation that there wasno increase in 
FoxP3 expression in synovial CD4+ T cells compared to blood in RApos patients was attributable to a high 
expression of FoxP3 in blood CD4+ T cells, indicating the involvement of blood due to the systemic nature of the 
disease. Also the presence of several cytokines in blood and SF, and especially a higher concentration of IL-8 
found in SF from RApos compared to RAneg and PsA, may reflect the differences in disease mechanisms. IL-8 is a 
chemokine involved in monocyte migration (Hayashida 2001), and elevated levels in SF favour the hypothesis of a 
selective recruitment of immune cells to the joint as part of the inflammatory process. 
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Anti-TNF drugs and the expression pattern of FoxP3 mRNA 
In our material, anti-TNF treatment had no general ffect on the expression of the different splice forms of FoxP3, 
CD25, and CTLA-4 mRNA (paper III). The three anti-TNF drugs used were the decoy receptor Etanercept, and the 
antibody-based therapies Adalimumab and Infliximab. There are different reports on the effect of anti-TNF drugs, 
many of which are looking solely on those patients who did benefit from the treatment. In line with this approach 
we performed a post hoc analysis of the RA patients who benefitted from the anti-TNF treatment.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. The changes in expression of FoxP3fl mRNA in the 
patients treated with the anti-TNF drugs A) Etanercept, B) 
Adalimumab, or C) Infliximab. The healthy controls are shown 
to the left in each diagram. The responders are defined as those 
patients with a change in DAS28 > 1.2 during 12 weeks of 
treatment. ∆Ct(FoxP3fl) = Ct(FoxP3fl) - Ct(CD4). 
 
 
 
 
 
 
 We observed a significant decrease in expression of FoxP3fl after 12 weeks of beneficial Etanercept 
treatment (figure 10A), where the expression was partially normalized and reduced from 4.6 times more t  3.2 
times more than the average HC. This reduction in expression of FoxP3fl, along with a concomitant reduction in 
CD25 expression from 2.9 to 2.0 times more than in the average HC, indicate a decrease in Treg cells towards that 
of healthy controls. Importantly, the expression of CTLA-4 was not significantly altered in these patien s and 
remained reduced at to almost half the amount as inHC (fold change 0.6). This lead to a change in the ratio 
between FoxP3fl and CTLA-4 towards that of HC, even though the ratio was still different as the HC has7.7 times 
more CTLA-4 than FoxP3fl mRNA and the Etanercept responders have 1.5. 
 In contrast, successful treatment with the antibody-based therapies Adalimumab and Infliximab did not 
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influence the expression of FoxP3fl (figure 10B+C), or the other mRNAs investigated. In the Infliximab group the 
opposite trend, an increase in expression of FoxP3fl, was seen. This trend towards an increase in expression of 
FoxP3fl in the Infliximab group was in accordance with findings by other groups (Ehrenstein 2004; Nadkarni 2007; 
Valencia 2006), and Nadkarni suggested that nTreg cells remained defective even after Infliximab treatment, and 
that the reported restoration of function could be du to induction of iTregs (Nadkarni 2007). Our data (paper I+II) 
support a previous report of an impaired CTLA-4 expr ssion in RA patients compared to healthy controls (Flores-
Borja 2008). In our biological samples, the anti-TNF treatment (decoy receptor or antibody-based therapy) did not 
return the expression of CTLA-4 to normal (paper III), which is also in agreement with previously published data 
(Flores-Borja 2008). Flores-Borja speculated that a reduced expression and functional abnormalities in Treg-
associated CTLA-4 could explain Treg defects in RA patients, and that anti-TNF therapy induces a population of 
iTregs using a TGF-β dependant suppressive mechanism as opposed to contact-dependant mechanism involving 
CTLA-4 (Flores-Borja 2008). Our data show decreased expression of CTLA-4 in RA patients supporting this 
theory.  
 Our data suggest that the TNF decoy receptor Etanercept and the antibody-based therapies Adalimumab and 
Infliximab have different effect on the expression of FoxP3 in responsive patients (paper III). We speculate that it 
is due to the differences in mechanisms between the two types of drugs. Etanercept is a decoy receptor which binds 
and eliminates both TNF-α and LT-α, while Adalimumab and Infliximab are neutralizing antibodies only targeting 
TNF-α. The two proteins TNF-α and LT-α share significant amino acid sequence homology and they bind to the 
same receptors TNFR1 and TNFR2. TNF-α is produced by a number of different cell types including monocytes, 
macrophages and T cells, while LT-α is produced by activated T cells (Tracey 2008). Further we speculate that LT-
α regulates FoxP3 expression in a subset of RA patients, and that individual patients may experience diff rent 
treatment effects depending on whether the TNF receptor ligand is mainly of monocyte/macrophage origin (TNF-
α) or T cell origin (LT-α). Overall, however, our findings support the view that anti-TNF treatment is mostly 
symptomatic and does not cure the underlying abnormality of the immune system. 
 
Definition of responders to the anti-TNF drugs 
We used the changes in DAS28 scores to identify the pati nts who benefitted from the anti-TNF treatment (paper 
III). We used part of the EULAR criteria for good responders: an improvement >1.2 in DAS28 score, based on the 
assumption that a change in DAS28 of more than 1.2 is a good response within 12 weeks regardless of the present 
score. For the patients included in our study (paper III), the current DAS28 at week 12 (x-axis) versus the change in 
DAS28 from week 0 to 12 (y-axis) were plotted (figure 11). In the Etanercept group (N=14), a total of 10 patients 
achieved a change in DAS28 score of more than 1.2 out of which three patients achieved remission and another 
three were scored with low disease activity. In the Adalimumab group (N=17), nine patients had a change of more 
than 1.2, and out of this group three patients achieved remission while one patient was scored with low disease 
activity. Finally, in the Infliximab group (N=17), 10 patients had a change in DAS28 score of more than 1.2, while 
no patients achieved remission, but three were reduced to low disease activity. 
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Figure 11. DAS28 scores at week 12 and the change in DAS28 
from week 0-12. The lines indicate EULAR defined remission at 
2.6; low disease activity 3.2; and high disease activity 5.1, as 
well as the change in DAS28 scores at 1.2. 
 
 
 
 
 
 
 
Responders versus non-responders 
We examined whether there was a different expression pattern of FoxP3 splice forms in the patients with a clinical 
response to anti-TNF compared to the non-responders (paper III). We were not able to identify baseline pr dictors 
of treatment response, i.e. identify patients who would benefit the most from anti-cytokine drugs based on its effect 
on the expression of FoxP3 mRNA isoforms present in CD4+ T cells in peripheral blood during therapy. Arthritis 
results from a multidimensional abnormality of the immune system, and effect of anti-TNF drugs seems to be 
based on other pathways than Tregs and FoxP3. 
 
Correlation between FoxP3 expression and clinical parameters  
One of the first questions we addressed was whether the expression of FoxP3 mRNA splice forms correlated to 
disease duration as a measure of the chronicity of the disease. There was no correlation, and disease duration had 
no influence on the expression of FoxP3 in RA patients (paper I). Factors having an impact on the FoxP3 mRNA 
expression were CRP, ESR and MTX. We speculate that a positive correlation between the amount of FoxP3 
mRNA and the biochemical markers of inflammation reflects a frustrated compensatory Treg response. The role of 
MTX is difficult to ascertain. The dosage of MTX reflects the disease activity; while at the same time may by itself 
reduce inflammatory markers. In our material, the FoxP3 expression varied widely in the patients withou  MTX, 
while the correlation was seen in those treated with this drug. Thus, MTX might be speculated to inhibit FoxP3 
expression in a dose-dependent manner, which would point towards a beneficial effect of MTX on the root f 
arthritis in contrast to the more superficial effect of anti-TNFs. However, confirmatory evidence of the possible 
MTX effect on FoxP3 needs to be presented before further considerations are made in this respect.  
 Our data are in agreement with Ehrenstein who report d a correlation between CRP and the percentage of 
CD4+CD25high T cells (not CD4+CD25low) (Ehrenstein 2004). Both expression data (paper I) and flow 
cytometry data (Ehrenstein 2004) indicate a relationship between inflammation and Tregs, where inflammtion is 
measured as CRP and Tregs as FoxP3 mRNA or CD4+CD25high on the protein level.  
 Since we observed a significant improvement in DAS28 and VAS scores within the first two weeks of anti-
TNF treatment (paper III), we addressed the question whether the individual changes in expression of FoxP3 
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mRNA within the first two weeks of treatment correlat d to different clinical parameters. We thus investigated the 
correlation between the changes in expression of FoxP3 (week 2-0) and the changes in DAS28 (week 12-0), doses 
of MTX and/or Prednisolone at baseline, female/male, RF status, and anti-CCP at baseline. There were no 
correlations between changes in FoxP3 expression and the DAS28 changes, doses of Prednisolone, or gender i  
either group. The doses of MTX at baseline correlated to the change in FoxP3fl in the Infliximab group, indicating 
an effect of MTX on the response. RF status and anti-CCP correlated to some of the changes in expression in the 
Etanercept group, but as the number of seronegative pati nts was only three, we disregarded these results. In 
conclusion, we could not definitively relate the changes in expression within the first two weeks to clinical data at 
baseline. 
 We then addressed the question whether the changes in expression of FoxP3 mRNA during 12 weeks of 
treatment correlated to changes in DAS28 scores or changes in CRP in the Etanercept responders. We chose to look 
at the Etanercept responders only as they exhibited s gnificant changes in expression during 12 weeks of treatment, 
while the responders to the antibody-based therapies did not. We found negative correlations between th  changes 
in DAS28 and FoxP3fl (r = -0.25) and FoxP3∆2 (r = -0.82) suggesting that a clinical improvement correlates to a 
reduction in FoxP3 mRNA expression. Similarly, we found significant negative correlation between the canges in 
DAS28 and CTLA-4 (r = -0.80) and also between changes in CRP and FoxP3∆2 (r = -0.67) all in agreement with 
the data from paper I indicating a relationship between inflammation and Tregs.  
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Supplementary experiments using DNA Microarray technology 
Introduction 
DNA microarray technology has been developed for gene expression profiling of thousands of transcripts, and 
many genes in various biological systems have been d monstrated to be differentially regulated. This technology 
has mainly been used in two ways: 
• As a tool for classification where disease signatures can be helpful in patient stratification (Aigner 2003; 
Heller 1997). This application requires, however, a rather large number of samples. 
• Screening for candidate genes or pathways involved in a disease process. 
 In both cases the results may primarily be considered hypothesis generating. Thus, comparing genes differentially 
expressed in synovial CD4+ T cells with CD4+ T cells from blood may elucidate inflammatory mechanisms and
possible targets, or simply confirm or refute theori s. These analyses may disclose a molecular signature of the 
difference between circulating CD4+ T cells and CD4+ T cells at the site of inflammation. In this study the 
GeneChip technology was chosen for transcript profiling due to the robustness and ease of use of this microarray 
technology. The principle of the DNA microarray analysis is outlined in figure 12. The details of the technique are 
beyond the scope of this thesis. For a detailed description of the technology please see: www.affymetrix.com.  
 
Total RNA
1-5 µg of starting material Double-stranded cDNA Biotinylated cRNA
Reverse transcription PCR amplification
Hybridization to the array
Staining with a steptavidin
phycoerythrin conjugate
 
Figure 12. The principle of the DNA Microarray analysis. Total RNA is isolated from the sample of interest, reverse-
transcribed into double-stranded cDNA, and further amplified by PCR resulting in biotinylated cRNA. The biotinylated 
product is hybridized to the array followed by staining with a streptavidin phycoerythrin conjugate. The microarray is then 
scanned in an instrument, where a laser excites the dye and a detector measures its emission.   
 
Methods 
DNA Microarray analysis was performed on CD4+ T cells isolated from blood and SF from three RAneg patients 
and three PsA patients. For logistic reasons it was not possible to include a group of RApos patients in he array 
study, as paired RNA samples from three RApos patients were not available, where the quality and amount f RNA 
met the high quality and large amount required for array analysis. The DNA Microarray technique required RNA 
preparations of 2-5 µg total RNA with a very high purity. Additionally, quantitative real-time RT-PCR was 
performed on the paired samples from two patients in each group.  
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Study population 
Patients were recruited consecutively from the outpatients’ clinic, Frederiksberg Hospital, Denmark. Inclusion 
criteria were: Flare of inflammatory arthritis in a knee joint; and indication for intra-articular injection of steroid. 
Exclusion criteria were: Osteoarthritis; contra-indications to joint aspiration; and the joint in question had been 
treated intra-articularly within the preceding month. Paired samples of blood and SF were collected from six 
patients; three diagnosed with rheumatoid arthritis (Arnett 1988) and three patients fulfilling the crite ia for 
psoriatic arthritis (Veale 1994). All six patients were seronegative. See table 3 for patient characteristics. 
 
Table 3. Patient characteristics.  
Patient ID Diagnosis Female/Male Age Disease duration prednisolone MTX QRT-PCR 
PsA 14 PsA F 63 5 No No Yes 
PsA 50 PsA F 57 37 No No No 
PsA 59 PsA F 46 2 No Yes Yes 
RAneg 21 RAneg F 45 9 No Yes Yes 
RAneg 28 RAneg M 62 1 Yes (oral) No No 
RAneg 58 RAneg F 52 10 No No Yes 
F: female; M: male; Age and disease duration in years; MTX: methotrexate; QRT-PCR: quantitative real-time RT-PCR applied 
to sample. 
 
cRNA and hybridisation 
Preparations of cRNA and hybridisation were performed according to the protocols from Affymetrix. Briefly, total 
RNA was prepared from cells using Trizol followed by RNA cleanup using a Qiagen kit as described in paper II. 
Synthesis of double-stranded cDNA was performed using an oligo dT primer with the T7 RNA polymerase 
recognition sequence appended. Subsequently, biotinylated nucleotides were incorporated by in vitro transcription 
using T7 RNA polymerase, and the resulting cRNA transcripts were fragmented before hybridisation. The Human 
Genome U133 Plus 2.0 Arrays were used, and the chips were scanned using a laser scanner according to 
instructions from Affymetrix.  
 
Treatment of data 
Hybridisation results were captured and further processed using the Microarray Suite MAS 5.0 (Affymetrix) 
software. All hybridisation results were scaled to 100 using all probe sets, and the data were analysed using Data 
Mining Tools 3.1 (DMT) from Affymetrix and DNA chip analyzer 1.3 (dCHIP) (Li 2001). Initially samples from 
blood (PB) were compared to samples from SF. Comparison was made between samples from same individuals, 
using the PB samples as baseline. This resulted in six data sets, one from each patient involved. In the subsequent 
analysis differentially regulated genes were isolated.  
 In the Affymetrix programme DMT differentially regulated genes were scored as either increased (I) with a 
signal log ratio ≥ 1 or decreased (D) with a signal log ratio ≤ -1. A signal log ratio of +/- 1 corresponded to a two-
fold up- or down-regulation. Furthermore, all D transcripts had to be scored as present in the PB sample, and all I 
transcripts had to be scored as present in the SF sample. In the dCHIP programme a gene was scored as 
differentially regulated if it had an expression value ratio SF/PB > 2.0 or PB/SF > 2.0; and a difference of more 
than 100 in signals between PB and SF samples.  
                                                                              Supplementary experim nts using DNA Microarray technology 
 
 38 
 Long lists of genes were created for each patient in each programme, but only genes scored as differentially 
regulated in both DMT and dCHIP in all three patient sets were analysed further. To be included in the list of 
differentially regulated genes common to all patients i  a diagnosis group, the direction of the change also had to be 
the same in all the patients of the group.  
                                                   
 
Figure 13. The number of differentially 
regulated genes common or specific for both 
patient groups using DMT and dCHIP.  
 
 
 
 In the RAneg patients, 555 genes were differentially regulated, and in the PsA patients it was 127 genes. 90 
genes were differentially regulated in both patient groups, and the direction of the change was the same, so that a 
gene up-regulated in one patient group was also up-regulated in the other patient group, see figure 13. The resulting 
numbers of differentially regulated genes using both programmes are listed in table 4. 
 
Table 4. The number of differentially regulated gene transcripts in each patient using DMT, dCHIP or the intersection of the 
results from both. Gene lists shown in bold was the basis of the Gene Ontology pathway analysis, and ge e lists marked with * 
was the basis of the Ingenuity Pathway analysis. Ptt: pa ients. 
Patient ID Data analysis Number of transcripts Increased Decreased 
 
DMT 4352 2053 2299 
dCHIP 2164 1109 1055 RAneg 21 
both 1979 1031 948 
 
DMT 5560 2050 3510 
dCHIP 3358 977 2381 RAneg 28 
both 2940 914 2026 
 
DMT 5194 2222 2972 
dCHIP 2808 1213 1595 RAneg 58 
both 2482 1132 1350 
 
DMT 1257 543 714 
dCHIP 601 256 344 RAneg (3 ptt) 
both 555* 245 310 
 
DMT 3849 1919 1930 
dCHIP 1476 1103 373 PsA 14 
both 1375 1016 359 
 
DMT 2011 1044 967 
dCHIP 1195 658 537 PsA 50 
both 931 503 428 
 
DMT 5565 2856 2709 
dCHIP 2572 1593 979 PsA 59 
both 2380 1447 933 
 
DMT 326 162 164 
dCHIP 145 90 55 PsA (3 ptt) 
Both 127* 79 48 
 
90 transcripts
(I: 48, D: 42)
465 transcripts
(I: 197, D: 268)
37 transcripts
(I: 31, D: 6)
RAneg, 3 patients PsA, 3 patients
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Results & Discussion 
In four out of six patients, both the DNA Microarray nalysis and the QRT-PCR were performed on the same 
samples. This gave me the opportunity to carry out a mutual validation of the techniques. Additionally to this 
analysis, the gene expression of a selected group of genes of special relevance will be discussed, and finally, a 
pathway analysis based on some of the gene lists shown in table 4 has been performed.  
 
Comparing DNA Microarray and quantitative real-time  PCR 
In this section I the two techniques DNA Microarray and quantitative real-time PCR were compared. The two 
techniques were applied to eight paired samples from our patients, but also the additional results from the four 
paired samples included in the DNA Microarray, but not run in quantitative real-time PCR, will be discu sed.  
 
GAPDH and CD4 
In the DNA Microarray analysis GAPDH and CD4 were scored as present in all 12 samples. GAPDH was scored 
as increased using PB samples as baseline, with a mean fold change of 1.8 for PsA and 2.0 for RAneg. This 
indicates that GAPDH is not a very good candidate for a housekeeping gene in these analyses, supporting the actual 
choice of CD4 as the internal reference when analyzing the QRT-PCR data. However, CD4 is not a perfect 
candidate either. On the DNA Microarrays, CD4 was not differentially regulated in three patients, while it was 
found decreased in one PsA patient (fold change: -1.5) and increased in two RAneg patients (fold change: 1.4 and 
1.9). Related to CD4, the four patients which were analysed with QRT-PCR, two PsA patients were scored as 
decreased (fold change: -1.5) and no change in the DNA Microarray analysis, and two RAneg patients were scored 
as increased (fold change: 1.4) and no change in the DNA Microarray analysis.  
 It should be noted that, when looking at QRT-PCR results, samples that differ by a factor of two in the
starting concentration of cDNA will theoretically be one cycle apart. Due to the semi-quantitative nature of as well 
QRT-PCR as the hybridisation readout from array studies, the QRT-PCR method requires a difference of 1 or more 
Ct to be considered reliable, and a fold change in the array readout of +/- 1.5 does not hamper the results. It is 
therefore concluded that a CD4 fold change within te range of +/- 1.5 does not influence the results, and thus 
support the use of CD4 as internal reference in the QRT-PCR analysis. 
 Comparing DNA Microarray analysis with QRT-PCR, it is not possible directly to compare the Ct values 
from the PCR system to the hybridisation signals from the array. Therefore, comparison of the fold changes in the 
paired samples was performed using PB samples as baseline.  
 
CD25, CTLA-4 and FoxP3 
With respect to CD25 and CTLA-4, the two methods are roughly in agreement. Table 5 lists the fold changes in the 
four patients in the PCR system and on the arrays. Also the change defined by Affymetrix is shown. A direct fold 
change comparison of the two methods with regard to the expression of FoxP3 splice forms is not possible, as the 
probes on the genechip do not distinguish between th  splice forms.  
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Table 5. Fold changes using PB samples as baseline.  
Patient CD25 PCR CD25 Array Change Array CTLA-4 PCR CTLA-4 Array  Change Array 
PsA 14 9.9 9.1 I 3.3 4.3 I 
PsA 59 1.0 -1.5 NC 1.4 -1.2 NC 
RAneg 21 1.1 1.6 I 1.1 1.9 I 
RAneg 58 1.3 2.1 I 0.83 (-1.2) 1.1 NC 
PCR: using QRT-PCR; Array: using DNA Microarray; I: Increased, NC: no change. 
 
There are three probes related to FoxP3 present on the array; one probe (221334_S_AT) covers sequences i  exons 
8, 9, 10, and 11, which means it recognises all splice forms. In the PCR system, three of the four patients have 
increased expression of the different splice forms using PB samples as baseline, while one patient showed a 
decrease in expression. Comparable results were obtained with the array system as the direction of the change was 
the same on the arrays. One of the two other probes (221333_AT) covers sequences in introns right after exon 11 
and right before exon 12, and as expected it gives no ignals on the arrays. The third probe is situated in exon 12 
after the stop codon and is therefore not relevant for this analysis. Based on this, it was concluded that the two 
methods are in general agreement, and the array dat was therefore used for further studies. 
 
Impurities/contamination 
Monocytes and macrophages also express limited amounts f CD4 on the cell surface, and since CD4-positive 
selection was performed, the possibility of impurities from these cell types were analysed. At first two rather 
specific markers of the monocyte/macrophage lineage wer  analysed: CD14 and CD68. CD14 was scored as 
present on all 12 arrays, while CD68 was scored as present on 9 of the 12 arrays. From this it was concluded that 
both monocytes and macrophages were present in the CD4+ cell populations. CD14 gave rise to rather high signals 
on the arrays in both PB and SF samples. However, this does not imply that the relative abundance of mnocytes 
was also high, since monocytes are both CD14high and CD4low when scored in flow cytometry. This means that a 
few monocytes can give rise to a strong CD14 mRNA signal. Secondly, contamination from B cells and CD8+ T 
cells were analysed.  CD19 and CD8 were scored as absent on all 12 chips, and it was therefore assumed that there 
were no contaminating B cells or CD8+ T cells in the CD4-positive selected cell preparations.  
 
Selected genes 
Th17 cells 
One type of cells, the Th17 cells, has recently attracted great attention in inflammatory conditions, specifically in 
immune-mediated tissue injury such as in the synovium in RA (Steinman 2007). The expression of IL-17 (IL-17A 
and IL-17F) appears to be restricted mainly to a smll group of activated CD4+ T cells, Th17 cells. CD161 is a 
marker of all human IL-17-producing T-cell subsets and is induced by the transcription factor RORγt (Maggi 
2010). The orphan nuclear receptor RORγt is the key transcription factor that orchestrates th  differentiation of this 
cell lineage, as RORγt induces transcription of the genes encoding IL-17 and the related cytokine IL-17F in naïve 
CD4+ T helper cells (Ivanov 2006). IL17A and IL17F, as well as RORγt, were scored as absent on the arrays, 
indicating the absence of Th17 cells in these samples. CD161 was scored as present in all samples with rather high 
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signals, indicating, perhaps, the presence of naïve CD4+ T cells underway to differentiation to Th17 cells as Th17 
cells originate from CD161+ naïve CD4+ T cells (Cosmi 2008).  
 
GARP  
Recently, GARP (Glycoprotein A Repetitions Predominantly) synonymous with LRRC32 (Leucine Rich Repeat 
Containing 32) was identified as a Treg-specific protein induced upon activation of the T cell receptor (TCR) 
(Probst-Kepper 2010). GARP is supposedly involved in the control of FoxP3 by a positive feedback loop and is 
supposed to be a key receptor involved in the maintenance of the phenotype and function of activated Tr g cells 
(Probst-Kepper 2010). GARP was scored as absent on all 12 arrays and thus not supporting the presence of active 
Tregs, unless the Tregs in these patients are not fu c ioning. Alternatively, the absence of GARP could be 
interpreted as the presence of iTregs as these cells do not up-regulate GARP (Probst-Kepper 2010). 
 
CD39 
Recently, CD39, an ectonucleotidase responsible for nzymatic cleavage of ATP to AMP, has been reported on the 
surface of human Tregs (Borsellino 2007; Mandapathil 2009). ATP is released during tissues injury and ctivates 
the immune system. A proposed anti-inflammatory mechanism for Treg cells is the catalytic inactivation and 
conversion of extracellular ATP to AMP by surface associated CD39 (Borsellino 2007). In all but one of the six PB 
samples CD39 was scored as absent, or present with a low signal. CD39 was scored as present in all six SF samples 
with medium high signals. This resulted in CD39 being scored as increased in SF in five of six patients wi h fold 
changes between 2.7 and 5.5. In one PsA patient there was no change in expression of CD39 between PB and SF, 
reflecting a higher signal in the blood sample. These data support the increased presence of Treg cells in SF. 
 
IL-7R 
Treg cells are among other things characterised in flow cytometry by low expression of IL-7 receptor (IL-7R; a 
heterodimer consisting of CD127 and CD132) and highexpression of CD25 (IL-2 receptor) on the cell surface 
(Seddiki 2006). IL-7R was present in all samples and gave rise to high signals on the arrays, and it was decreased 
in all SF samples except one PsA SF sample. These data indicate the presence of a mix of Treg cells and resting 
CD4+ T cells as the latter express high levels of IL-7R and very low levels of CD25 on the cell surface. IL-7 itself 
seems to be involved in the homeostasis of T cells in humans with a selective increase in non-Treg CD4+ T cells 
(Rosenberg 2006), but no IL-7 protein was found in the PB or SF samples, supporting the suggestion that the T 
cells present in the joint were recruited to the sit of inflammation. 
 
IL-2 
IL-2 is a T cell growth factor produced by conventio al T cells upon exposure to antigens, and it is critical for the 
development and peripheral expansion of CD4+CD25+ regulatory T cells (Nelson 2004; Scheffold 2005). IL-2 was 
scored as absent on all 12 arrays, indicating the presence of a large number of already committed Tregcells as well 
as naïve T cells among these CD4+ T cells isolated, as only activated T cells, and not Tregs, produce IL-2 
(Scheffold 2005). Additionally, the cytokine IL-2 was not measurable in any of the PB or SF samples, which is in 
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agreement with previous results by other groups (Steiner 1999; Tukaj 2010). These data indicate that CD4+ T cells, 
including Tregs, present in SF are recruited to the site of inflammation rather than proliferate in the joint, cf. later. 
 
Ki-67 protein 
Ki-67 protein (MKI67; antigen identified by monoclonal antibody Ki-67) is a proliferation marker present only 
during active phases of the cell cycle, and absent in resting cells (Scholzen 2000). In this data set th  Ki-67 protein 
was scored as absent or present with very low signals on the arrays supporting the hypothesis of Tregs being 
recruited to the joint rather than proliferate at the site. Additionally, it indicates the absence of activated T cells, as 
activated T cells proliferate. 
 
CCR4 
The issue of recruitment versus local proliferation has been addressed by others (Flytlie 2009; Iellem 2001; Jiao 
2007; Oo 2010), and Jiao 2007 found that Treg cellsin SF from RA patients expressed high levels of especially 
CCR4, a chemokine receptor possibly involved in controlling the trafficking of Treg cells into inflammatory tissues 
(Wei 2006). CCR4 is also reported as expressed on circulating CD4+ memory T cells, including skin-homing T 
cells (Flytlie 2009; Iellem 2001), and is therefore f interest regarding PsA. Moreover, CCR4 is up-regulated upon 
TCR-mediated activation and is more likely a marker for activated T cells (Iellem 2001). In this limited data set, 
differing results were found with increased expression in two PsA patients and one RAneg patient while t e 
remaining three patients had no change in expression between PB and SF samples. The signals on the arrays varied 
between medium high signals in the three SF samples with increased expression to being scored as absent in two 
other SF samples. The two patients (one RAneg and one PsA) with CCR4 scored absent both had disease duration 
of 1- 2 years. Flytlie 2009 proposed that CCR4 exprssing CD4+ T cells could be involved in spreading psoriasis to 
the joints as CCR4 was shown to be necessary for the migration of T cells to the skin, and both CCR4+ cells and 
the CCR4 ligand MDC/CCL22 were increased locally in the inflamed synovial membrane. However, my data does 
not necessarily support this hypothesis as the newly diagnosed PsA patient did not express CCR4 in SF.  
 
Pathway study 
Due to the large amounts of data generated in an arr y study, a pathway analysis is an obvious choice f approach 
to systematise the differentially expressed genes. The gene lists shown in bold in table 4 were analysed further 
using the Gene Ontology (GO) classification browser in the NetAffx™ Analysis Center (www.affymetrix.com) and 
the Ingenuity Pathway Analysis (IPA) software (www.ingenuity.com).  
 Using the GO annotations, several pathways were represented among the differentially regulated genes. 
They are listed in table 6. Some genes are represented in more than one pathway, for example it was noticed that 
vitamin D receptor is present in the two pathways “nuclear receptors” and “ovarian infertility genes”. The pathways 
were grouped into three categories: “Immune response a d immune cell trafficking”, “Cell cycle and metabolism”, 
and “Miscellaneous”.  
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 In the category “Immune response and immune cell trafficking” several pathways are involved in cell 
migration, which may relate to the accumulation of immune cells in the SF: G-protein coupled receptors are 
associated with many cell surface receptors including chemokine receptors which may be especially relevant to 
homing of regulatory T cells to the synovium (Flytlie 2009). Calcium is part of signal transduction pathways such 
as G protein-coupled receptors, and the pathway “Calcium regulation in cardiac cells” includes genes involved in 
ion transport, protein binding, and receptor signalli g, and does not indicate the presence of cardiac cells in the 
synovium. Integrins are cell adhesion molecules also involved in cell migration, and Wnt proteins are involved in 
calcium signalling through G proteins and gene activ tion in T cells. The TGF-β signalling pathway is involved in 
many cellular processes including cell differentiation, cell growth, and apoptosis. The differentiation of Treg cells 
requires TGF-β but is dependent on the transcription factor FoxP3. The inflammatory response pathway is relevant 
for this dataset, as arthritis is considered an inflammatory disorder. The category “Cell cycle and metabolism” 
comprises of several pathways involved in cell cycle, ell metabolism and growth, and includes DNA replication, 
mRNA processing, and glycolysis. The category “Miscellaneous” constitute the rest. 
 
Table 6.     RAneg          PsA 
Gene Ontology pathways             Increased    Decr ased     Increased   Decreased 
           (Total 245)   (Total 310)    (Total 79)    (Total 48) 
Immune response and immune cell trafficking 
G-protein coupled receptor protein signalling pathway 21 5 4 4 
Integrin-mediated cell adhesion 1 2 0 2 
Calcium regulation in cardiac cells 7 4 4 1 
Inflammatory Response Pathway 7 2 4 0 
TGF-Beta Signalling Pathway 1 4 2 1 
Wnt signalling 0 2 1 1 
     
Cell cycle and metabolism 
Cell cycle 3 2 1 0 
G1-to-S cell cycle 1 3 1 0 
Glycolysis and Gluconeogenesis 4 0 0 0 
Krebs-TCA Cycle 0 1 0 0 
Pentose Phosphate Pathway 0 1 0 1 
mRNA processing 0 5 0 0 
Ribosomal Proteins 0 4 0 1 
DNA replication 0 0 1 0 
Nuclear Receptors 2 0 1 0 
 
Miscellaneous     
Apoptosis 1 3 0 0 
Circadian Exercise 3 0 1 0 
Complement Activation Classical 3 0 0 0 
Fatty Acid Degradation 3 1 0 0 
Hypertrophy model 1 0 1 0 
Ovarian Infertility Genes 2 2 1 0 
Prostaglandin synthesis regulation 2 0 0 0 
Smooth muscle contraction 3 1 1 1 
Statin Pathway 0 0 1 0 
Striated muscle contraction 1 0 0 0 
 
Analysis based on gene list shown in bold in table 4 
 
 Using the IPA software, it was investigated if there was an association betwe n the differentially regulated 
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genes and a specific pathway, and whether this was due to chance. Based on gene lists marked with * in table 4, 
IPA generated a list of canonical pathways associated with the dataset, as well as a p-value and a ratio for each 
pathway. Fisher’s exact test was used to calculate a p-value determining the probability that the association 
between the genes in the dataset and the canonical pathway is explained by chance alone. The ratio was calculated 
as: the number of molecules in a given pathway that is differentially regulated divided by the total number of 
molecules that makes up the given pathway.  
 However, the canonical pathways linked by IPA to the dataset were primarily pathways involving HLA 
molecules (MHC II) which are expressed on monocytes, but also on activated T cells and B cells. MHC II is highly 
expressed on monocytes giving rise to a strong fluorescence signal in flow cytometry compared to a low 
fluorescence signal from activated T cells. Together with the absence of IL-2 expression in the analysed CD4+ 
cells this indicates that the MHC II signals originate from monocytes. Hence, the pathways linked to the dataset by 
IPA reflect the minority of monocytes in the samples and not the CD4+ T cells present.  
 Through another feature of IPA it was possible to identify the biological functions that were most significant 
to the molecules differentially regulated in the SF samples compared to the PB samples. The molecules associated 
with biological functions in Ingenuity’s Knowledge Base were considered for the analysis. Right-tailed Fisher’s 
exact test was used to calculate a p-value determining the probability that each biological function assigned was 
due to chance alone. The molecular and cellular functio s are listed in table 7.  
 
Table 7. 
Ingenuity Pathway Analysis - Molecular and cellular functions 
 
RAneg  
Name                p-value  # Molecules 
Cell-To-Cell Signalling and Interaction  4.57*10-7 - 2.10*10-2  45 
Cellular Growth and Proliferation  7.55*10-7 - 2.44*10-2  86 
Cellular Movement   2.25*10-5 - 2.45*10-2  50 
Cellular Development   5.25*10-5 - 2.51*10-2 47 
Cell Cycle    3.18*10-4 - 2.16*10-2  16 
 
PsA  
Name                p-value  # Molecules 
Cellular Movement   2.72*10-7 - 3.31*10-2  23 
Cellular Growth and Proliferation  1.41*10-6 - 3.31*10-2  32 
Cell-To-Cell Signalling and Interaction  4.88*10-5 - 3.31*10-2  17 
Cell Cycle    6.96*10-5 - 3.31*10-2  7 
Cell Death    1.94*10-4 - 3.31*10-2  28 
 
Analysis based on gene list marked with * in table 4 
 
 In conclusion the array data point mostly towards the presence of cell-traffic related molecules as well as to 
antigen presentation due to monocyte contamination. This indicates that the cells present in the SF are cells 
attracted to the site of inflammation.
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Closing remarks 
Several questions arose regarding FoxP3 in RA: What kind of Tregs are increased, nTregs or iTregs? What are the 
implications of an increase in numbers of iTregs rather than nTregs or vice versa? CTLA-4 is thought to play an 
important part in the suppressive function of nTregs, and the lack of a concomitant increase in CTLA-4 expression 
suggests the presence of dysfunctional nTregs in arthritis patients. However, based on our data we cannot exclude 
the possibility of an increase of in vivo generated iTregs rather than dysfunctional nTregs. The importance of 
CTLA-4 is highlighted by the fact that Abatacept, which is a CLTA-4-IgG fusion protein, is effective in RA, and 
one could speculate that Abatacept mimics the actions of functional nTregs.  
 The iTregs are generated in the periphery after TCR activation and in the presence of TGF-beta and, ulike 
nTregs, they are reported to be resistant to the influe ce of IL-6. The cytokine IL-6 can convert nTregs to Th17 
cells, while the iTregs are resistant to this cytokine and may retain their suppressive function at inflammatory sites, 
such as SF, rich in IL-6. It is quite possible that nTregs and iTregs have different roles in immune responses and 
react differently in an inflammatory milieu. Fujimoto suggested that “the TCR repertoire between nTreg and iTregs 
are different and that nTregs may be important for he maintenance of self-tolerance via recognizing self-antigens, 
whereas iTregs generated from conventional T cells may be involved in tolerance to non-self antigens” (Fujimoto 
2011). Based on their study in mice which implied a ifferent effect of IL-6 on nTregs and iTregs, Fujimoto further 
suggested that “IL-6 may thus enhance foreign antige -specific immune response by acting differently on nTregs 
and iTregs” (Fujimoto 2011). Using this model in RA, the high levels of IL-6 reported in SF from RA patients by 
us and others would tip the balance towards iTregs and enhance a specific immune response against foreign 
antigens when a response against self antigens is needed.  
 Another relevant question came up while interpreting he QRT-PCR data: Are we looking at activated T cells 
rather than Tregs? Based only on the QRT-PCR data we cannot say for certain because Tregs and activated T c lls 
all express high levels of CD25 and also CTLA-4, but ased on the DNA Microarray data the answer is no. The 
activation/proliferation markers IL-2 and Ki-67 were scored as absent or present with low signals on the arrays. 
Additionally, IL-7R was present with rather high signals on the arrays indicating the presence of resting CD4+ T 
cells, as they express high levels of IL-7R and very low levels of CD25 on the cell surface. FoxP3 is transiently 
expressed in activated T cells, but according to our array data there were no activated T cells in these samples, and 
increased FoxP3 expression therefore indicated increased Treg counts. From this we conclude that we are looking 
at a mix of resting CD4+ T cells and Treg cells, but that we cannot distinguish between nTregs and iTregs.  
 An alternative splice form of CTLA-4 has been reported, lacking the trans-membrane region encoded by 
exon two resulting in a soluble form of the protein. Our probe and primers are located in exon two, and we can only 
detect the full length CTLA-4 mRNA resulting in the membrane form. The membrane version of CTLA-4 is up-
regulated upon T cell activation while the soluble form is down-regulated by T cell activation. This information 
further supports the data on the lack of activated T cells in our samples as membrane CTLA-4 is not up-regulated 
while FoxP3 is.  
 We addressed the question of the increased presence of Tregs in SF, enrichment or proliferation, and based 
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on our data we favour the concept of enrichment. According to the array data the proliferation marker Ki-67 is not 
present, indicating the absence of proliferating Tregs, and leaving two options: selective recruitment (nTreg) or 
induction (iTreg). The presence of cell-traffic relat d molecules, according to the array data, could be in support of 
selective recruitment of nTregs but could also be du  to general trafficking of immune cells attracted to the site of 
inflammation, and the absence of GARP on the array m indicate the presence of iTregs as these cells do not up-
regulate GARP. 
 Possibly, there is a difference between activated nd non-activated T cells regarding the expression of FoxP3 
mRNA splice forms. In our data set, looking at non-activated T cells, we saw a trend towards a difference in the 
ratio between the full length and ∆2 splice of forms of FoxP3 between RA patients and HC. Previously a ∆2∆7 
splice form was identified as over-expressed in T cells from patients suffering from Sézary Syndrome, and also ex 
vivo stimulated CD4+CD25+ T cells had an increased expression of a ∆7 splice form of FoxP3. These results differ 
from ours as we only detected very small amounts of FoxP3 splice forms lacking exon seven in RA patients a d 
HC. According to the array data these T cells were not activated, and that could explain the lack of either ∆7 splice 
form. 
 Anti-TNF drugs do have an effect in RA as demonstrated with changes in DAS28 and VAS scores. The 
effect on FoxP3 expression in our dataset was not ueq ivocal as we observed a decrease in the Etanercept group 
and a trend towards an increase in the Infliximab group when looking only at patients who benefitted from the 
treatment. It is difficult to be conclusive about the effect of anti-TNF therapies on Tregs, possibly because they are 
not the primary target and only influenced by changes in the entire inflammatory milieu. 
 The ongoing disease despite a relative abundance of Tregs in the blood and even more so locally in the joint 
is a paradox. Accumulation of Tregs close to the sit  of inflammation may represent a futile attempt to suppress the 
auto-reactive inflammation. The Tregs may be inherently dysfunctional or rendered dysfunctional due to the local 
inflammatory milieu. 
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Future perspectives 
Flow cytometry or Western blot to verify the protein xpression is an obvious choice for further studies, especially 
if it has become possible to buy splice form specific antibodies for flow cytometry and/or Western blot. 
Furthermore, functional studies elucidating possible suppressive mechanisms targeting the pathogenic processes 
involved in RA could be used to identify targets for future therapy. Also it would be important to identify the 
predicted differences in specificity of the TCR repertoire between nTregs and iTregs. The recently developed 
technologies of MHC multimer reagents, for example the DextramerTM technology, enable detection of antigen-
specific CD8+ T cells. When this technology includes tection of antigen-specific CD4+ T cells we canaddress 
this question and a whole new range of possibilities emerges.   
 Therapy using Treg cells is the next step. There are several approaches to consider when contemplating Treg 
cell therapy: activation and expansion of antigen-specific nTregs in vivo, the use of in vitro expanded nTregs 
transferred to the patient, or the conversion of naïve T cells to antigen-specific iTregs in vivo or in vitro. Future 
studies to identify specific surface markers that can differentiate between Treg cells and effector cells are essential 
for future manipulation of Tregs. Treg cells proliferate poorly in vitro and the expansion of possible contaminating 
effector T cells could be a factor. Also, it is important to elucidate the mechanisms of action of Tregs in order to be 
able to control their function in a clinical setting. Immunotherapy with Treg cells has been used for experimental 
treatment of acute graft-versus-host disease (Brunstein 2011). The study by Brunstein and colleagues wa  a “first-
in-human” clinical trial and demonstrated that it is possible and safe, and that it decreased the risk of acute graft-
versus-host disease in the recipients of these ex vivo expanded umbilical cord blood Tregs. One could speculate that 
the mechanism of action in the case of these ex vivo expanded Tregs is the work of CTLA-4 co-stimulation and the 
use of Abatacept would be equally successful. The effect of Treg cell therapy in RA is debatable, and if, as our data 
and others suggest, Tregs are dysfunctional in RA, the challenges regarding future Treg therapy in RA will be to 
expand the right Treg population and not a dysfunctio al one. Another strategy could be to use ex vivo expanded 
umbilical cord blood Tregs as described by Brunstei. However allograft is not feasible when considering the pros 
and cons and would probably only be used in extremely severe cases. Whether Treg cell therapy will have n effect 
in RA patients still remains unanswered.  
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Appendix A 
Supplementary figures 
10-fold dilutions series of cDNA using primer sets for A) GAPDH, B) CD25, C) CTLA-4, D) FoxP3∆2 and E) FoxP3∆2∆7. 
The slopes were determined from the trendline equations. 
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